Cancer Research and Treatment

Original Articles

Genitourinary cancer

Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies: Sung Wook Cho, Sung Hee Lim, Ghee Young Kwon, Chan Kyo Kim, Won Park, Hongryull Pyo, Jae Hoon Chung, Wan Song, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park; Cancer Res Treat. 2024;56(3):893-897. Published online February 15, 2024; DOI: https://doi.org/10.4143/crt.2024.015

Purpose
Bladder preservation chemoradiotherapy (CRT) in patients with a clinical complete response (cCR) following cisplatin-based neoadjuvant chemotherapy (NAC) is a promising treatment strategy for muscle-invasive bladder urothelial carcinoma (MIBC). A combined analysis of raw data from two prospective phase II studies was performed to better evaluate the feasibility of selective bladder preservation CRT.
Materials and Methods
The analysis was based on primary efficacy data from two independent studies, including 76 MIBC patients receiving NAC followed by bladder preservation CRT. The efficacy data included metastasis-free survival (MFS) and disease-free survival (DFS). For the present analysis, starting point of survival was defined as the date of commencing CRT.
Results
Among 76 patients, 66 had a cCR following NAC. Sixty-four patients received gemcitabine and cisplatin (GC) combination chemotherapy in neoadjuvant setting, and 12 received nivolumab plus GC. Bladder preservation CRT following NAC was generally well-tolerated, with low urinary tract symptoms being the most common late complication. With a median follow-up of 64 months, recurrence was recorded in 43 patients (57%): intravesical only (n=20), metastatic only (n=16), and both (n=7). In 27 patients with intravesical recurrence, transurethral resection, and Bacillus Calmette-Guerin treatment was given to 17 patients. Salvage cystectomy was performed in 10 patients. Median DFS was 46.3 (95% confidence interval [CI], 25.1 to 67.5) months, and the median MFS was not reached. Neither DFS nor MFS appeared to be affected by any of the baseline characteristics. However, DFS was significantly longer in patients with a cCR than in those without (hazard ratio, 0.465; 95% CI, 0.222 to 0.976).
Conclusion
The strategy of NAC followed by selective bladder preservation CRT based on the cCR is feasible in the treatment of MIBC. A standardized definition of cCR is needed to better assess disease status post-NAC.

Citations

Citations to this article as recorded by

News and prospects on radiotherapy for bladder cancer: Is trimodal therapy becoming the gold standard?
Olivier Riou, Christophe Hennequin, Jonathan Khalifa, Paul Sargos
Cancer/Radiothérapie.2024; 28(6-7): 623. CrossRef

2,613 View
140 Download
1 Web of Science
1 Crossref

Physical Activity and Bladder Cancer Risk: Findings of the Japan Collaborative Cohort Study: Hang An, Keyang Liu, Kokoro Shirai, Ryo Kawasaki, Akiko Tamakoshi, Hiroyasu Iso; Cancer Res Treat. 2024;56(2):616-623. Published online October 6, 2023; DOI: https://doi.org/10.4143/crt.2023.962

Abstract PDF Supplementary Material PubReader ePub: Purpose
The association of physical activity with the risk of bladder cancer remains inconsistent among Asian populations. We aimed to examine the association in a large Japanese cohort.
Materials and Methods
In a population-based prospective cohort study, a total of 50,374 Japanese adults aged 40-79 years without a history of cancer or cardiovascular disease who had information on physical activity from self-administrated questionnaires were used for analysis. We performed Cox proportional hazard models to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for incident bladder cancer after adjusting for several potential confounders.
Results
During the median 17.5 years of follow-up, 153 incident bladder cancers (116 men and 37 women) were identified. After the multivariable adjustment, HRs (95% CI) of bladder cancer concerning those with recreational sports participation of 1-2 hr/wk, 3-4 hr/wk, and 5 hr/wk and more were 0.67 (0.38-1.20), 0.79 (0.36-1.74), and 0.28 (0.09-0.89), respectively (p for trend=0.017). Compared with mostly sitting at the workplace, occupational physical activity of standing and walking were associated with a lower risk of bladder cancer (HR, 0.53 [95% CI, 0.32 to 0.85]). Hours of daily walking were not associated with the risk. The lower risk of bladder cancer was more evident for recreational sports (HR, 0.33 [95% CI, 0.10 to 1.00]), and for occupational standing and walking activity at work (HR, 0.57 [95% CI, 0.33 to 0.98]) among men.
Conclusion
Recreational sports participation and occupational physical activity were inversely associated with the risk of bladder cancer among Japanese, especially in men.

3,953 View
178 Download

TNM-Based Head-to-Head Comparison of Urachal Carcinoma and Urothelial Bladder Cancer: Stage-Matched Analysis of a Large Multicenter National Cohort: Sang Hun Song, Jaewon Lee, Young Hwii Ko, Jong Wook Kim, Seung Il Jung, Seok Ho Kang, Jinsung Park, Ho Kyung Seo, Hyung Joon Kim, Byong Chang Jeong, Tae-Hwan Kim, Se Young Choi, Jong Kil Nam, Ja Yoon Ku, Kwan Joong Joo, Won Sik Jang, Young Eun Yoon, Seok Joong Yun, Sung-Hoo Hong, Jong Jin Oh; Cancer Res Treat. 2023;55(4):1337-1345. Published online April 17, 2023; DOI: https://doi.org/10.4143/crt.2023.417

Abstract PDF Supplementary Material PubReader ePub

Purpose
Outcome analysis of urachal cancer (UraC) is limited due to the scarcity of cases and different staging methods compared to urothelial bladder cancer (UroBC). We attempted to assess survival outcomes of UraC and compare to UroBC after stage-matched analyses.
Materials and Methods
Total 203 UraC patients from a multicenter database and 373 UroBC patients in single institution from 2000 to 2018 were enrolled (median follow-up, 32 months). Sheldon stage conversion to corresponding TNM staging for UraC was conducted for head-to-head comparison to UroBC. Perioperative clinical variables and pathological results were recorded. Stage-matched analyses for survival by stage were conducted.
Results
UraC patients were younger (mean age, 54 vs. 67 years; p < 0.001), with 163 patients (80.3%) receiving partial cystectomy and 23 patients (11.3%) radical cystectomy. UraC was more likely to harbor ≥ pT3a tumors (78.8% vs. 41.8%). While 5-year recurrence-free survival, cancer-specific survival (CSS) and overall survival were comparable between two groups (63.4%, 67%, and 62.1% in UraC and 61.5%, 75.9%, and 67.8% in UroBC, respectively), generally favorable prognosis for UraC in lower stages (pT1-2) but unfavorable outcomes in higher stages (pT4) compared to UroBC was observed, although only 5-year CSS in ≥ pT4 showed statistical significance (p=0.028). Body mass index (hazard ratio [HR], 0.929), diabetes mellitus (HR, 1.921), pathologic T category (HR, 3.846), and lymphovascular invasion (HR, 1.993) were predictors of CSS for all patients.
Conclusion
Despite differing histology, UraC has comparable prognosis to UroBC with relatively favorable outcome in low stages but worse prognosis in higher stages. The presented system may be useful for future grading and risk stratification of UraC.

Citations

Citations to this article as recorded by

Clinical Presentation and Targeted Interventions in Urachal Adenocarcinoma: A Single-Institution Case Series and Review of Emerging Therapies
Akshay Mathavan, Akash Mathavan, Rodrigo Murillo-Alvarez, Kriti Gera, Urszula Krekora, Aaron J. Winer, Mohit Mathavan, Ellery Altshuler, Brian Hemendra Ramnaraign
Clinical Genitourinary Cancer.2024; 22(1): 67. CrossRef
Robotic‐assisted approaches to urachal carcinoma: A comprehensive systematic review of the safety and efficacy outcomes
Caio Vinícius Suartz, Lucas Motta Martinez, Pedro Henrique Brito, Carlos Victori Neto, Maurício Dener Cordeiro, Luiz Antonio Assan Botelho, Fábio Pescarmona Gallucci, José Maurício Mota, William Carlos Nahas, Leopoldo Alves Ribeiro‐Filho
BJUI Compass.2024; 5(3): 327. CrossRef

3,356 View
204 Download
2 Web of Science
2 Crossref

Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Hongsik Kim, Byong Chang Jeong, Joohyun Hong, Ghee Young Kwon, Chan Kyo Kim, Won Park, Hongryull Pyo, Wan Song, Hyun Hwan Sung, Jung Yong Hong, Se Hoon Park; Cancer Res Treat. 2023;55(2):636-642. Published online October 6, 2022; DOI: https://doi.org/10.4143/crt.2022.343

Abstract PDF PubReader ePub

Purpose
The activity and safety of neoadjuvant nivolumab plus gemcitabine/cisplatin (N+GC) were tested in patients with muscle-invasive bladder urothelial carcinoma (MIBC).
Materials and Methods
In a prospective phase II trial, patients with cT2-T4a N0 MIBC who were eligible for cisplatin and medically appropriate to undergo radical cystectomy (RC) were enrolled. Treatment with nivolumab 3 mg/kg on days 1 and 15 plus GC (cisplatin 70 mg/m2 on day 1, and gemcitabine 1,000 mg/m2 on days 1, 8, and 15) was repeated every 28 days up to 3 or 4 cycles, depending on the surgery schedules. The primary endpoint was pathologic complete response (pCR, ypT0). Secondary endpoints included pathologic downstaging (≤ ypT1), disease-free survival (DFS), and safety.
Results
Between September 2019 and October 2020, 51 patients were enrolled. Neoadjuvant N+GC was well tolerated. Among 49 patients who completed neoadjuvant N+GC, clinical complete response (cCR) was achieved in 59% of intent-to-treat (ITT) population. RC was performed in 34 (69%) patients. pCR was achieved in 24% (12/49) of ITT population and 35% (12/34) of RC patients. Median DFS was not reached. Over a median follow-up of 24 months, 12 patients experienced disease recurrence and were treated with palliative therapy or surgery. Although 12 patients declined surgery and were treated with concurrent chemoradiotherapy, DFS was longer in patients with cCR after neoadjuvant therapy than those without. Preoperative programmed death-ligand 1 (PD-L1) did not correlate with pCR or pathologic downstaging rates.
Conclusion
Neoadjuvant N+GC was feasible and provided meaningful pathologic responses in patients with MIBC, regardless of baseline PD-L1 expression (ONO-4538-X41; CRIS.nih.go.kr, KCT0003804).

Citations

Citations to this article as recorded by

Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis
Shibo Huang, Yanping Huang, Chunyan Li, Yiwen Liang, Miaoyan Huang, Raoshan Luo, Weiming Liang
Frontiers in Immunology.2024;[Epub] CrossRef
What’s new about the tumor microenvironment of urothelial carcinoma?
João Queirós Coelho, Maria João Ramos, Ridhi Ranchor, Rita Pichel, Laura Guerra, Hugo Miranda, Joana Simões, Sérgio Xavier Azevedo, Joana Febra, António Araújo
Clinical and Translational Oncology.2024; 26(7): 1549. CrossRef
A bibliometric insight into neoadjuvant chemotherapy in bladder cancer: trends, collaborations, and future avenues
Yi Huang, Chengxiao Liao, Zefeng Shen, Yitong Zou, Weibin Xie, Qinghua Gan, Yuhui Yao, JunJiong Zheng, Jianqiu Kong
Frontiers in Immunology.2024;[Epub] CrossRef
Bladder-sparing treatment using tislelizumab combined with gemcitabine/cisplatin in selected patients with muscle-invasive bladder cancer: a real-world study
Cheng Luo, Shuhang Luo, Wumier Wusimanjiang, Zongren Wang, Ping Liu, Bin Wang, Dan Yuan, Hao Lin, Abai Xu, Nan Deng, Kaihui Wu, Xuejin Zhu, Peng Xu, Junxing Chen, Bin Huang
Clinical and Translational Oncology.2024; 26(7): 1759. CrossRef
Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies
Sung Wook Cho, Sung Hee Lim, Ghee Young Kwon, Chan Kyo Kim, Won Park, Hongryull Pyo, Jae Hoon Chung, Wan Song, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park
Cancer Research and Treatment.2024; 56(3): 893. CrossRef
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
Thomas Powles, James W.F. Catto, Matthew D. Galsky, Hikmat Al-Ahmadie, Joshua J. Meeks, Hiroyuki Nishiyama, Toan Quang Vu, Lorenzo Antonuzzo, Pawel Wiechno, Vagif Atduev, Ariel G. Kann, Tae-Hwan Kim, Cristina Suárez, Chao-Hsiang Chang, Florian Roghmann, M
New England Journal of Medicine.2024; 391(19): 1773. CrossRef
Klassische Chemotherapie, Immuntherapie oder adjuvante Strahlentherapie – Wie können wir die onkologischen Ergebnisse der radikalen Zystektomie verbessern?
Pia Paffenholz, Stefanie Zschäbitz
Die Urologie.2024; 63(10): 994. CrossRef
Recent developments in perioperative combination therapy in muscle-invasive bladder cancer
Jan-Jaap J. Mellema, Bas W.G. van Rhijn, Michiel S. van der Heijden
Current Opinion in Urology.2023; 33(5): 404. CrossRef

5,684 View
275 Download
6 Web of Science
8 Crossref

Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy: Ryul Kim, Jung Yong Hong, Jeeyun Lee, Ghee Young Kwon, Byong Chang Jeong, Se Hoon Park; Cancer Res Treat. 2022;54(3):894-906. Published online November 17, 2021; DOI: https://doi.org/10.4143/crt.2021.854

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to explore the genomic and transcriptomic landscape of bladder cancer (BC) and its implication for treatment with an immune checkpoint inhibitor (ICI).
Materials and Methods
We analyzed whole-exome and -transcriptome sequences of tumor samples from 64 BC patients who underwent surgical resection with either transurethral resection or radical cystectomy. For exploratory purposes, programmed death-ligand 1 (PD-L1) expression was evaluated in a subset of patients (n=57) including those treated with ICI (n=8).
Results
We identified frequent molecular dysregulations in chromatin regulatory genes (KDM6A, ARID1A, MLL2, and STAG2) and recurrent copy number alterations. Thirty-five samples (54.7%) were PD-L1–positive (PD-L1 combined positive score ≥ 1) with a significantly higher exonic tumor mutational burden (TMB) compared to PD-L1–negative BC samples (p=0.010). We observed that various immune-responsive pathways, including the PD-L1 signaling pathway, were enriched significantly in PD-L1–positive BCs. Interestingly, genes in the CTLA4 pathway were enriched significantly in PD-L1–positive BC as well. Among eight patients who received ICI, progressive disease was confirmed in one patient, whose tumor had low exonic TMB, negative PD-L1 status, and a relatively colder microenvironment.
Conclusion
Gaining new insights into the molecular landscape of BC will improve treatment strategies. Our analysis suggests a rationale for studying dual checkpoint inhibition against BC.

Citations

Citations to this article as recorded by

The role of lysine-specific demethylase 6A (KDM6A) in tumorigenesis and its therapeutic potentials in cancer therapy
Li-Juan Chen, Xin-Yang Xu, Xiao-Dan Zhong, Yan-Jun Liu, Ming-Hui Zhu, Fan Tao, Chang-Yun Li, Qiu-Sheng She, Guan-Jun Yang, Jiong Chen
Bioorganic Chemistry.2023; 133: 106409. CrossRef
A novel cuproptosis-related lncRNAs signature predicts prognostic and immune of bladder urothelial carcinoma
Zheng Zhou, Yusong Zhou, Wei Liu, Jing Dai
Frontiers in Genetics.2023;[Epub] CrossRef
Implication of KDM6A in Bladder Cancer
Marianne Matar, Gilles Prince, Ibrahim Hamati, Maria Baalbaky, Jonas Fares, Marc Aoude, Charbel Matar, Hampig Raphael Kourie
Pharmacogenomics.2023; 24(9): 509. CrossRef
Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
Joohyun Hong, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park
Biomedicines.2022; 10(8): 2005. CrossRef
Antineoplastics

Reactions Weekly.2022; 1933(1): 61. CrossRef
Cuproptosis-related lncRNA signatures predict prognosis and immune relevance of kidney renal papillary cell carcinoma
Tongjin Xie, Bin Liu, Dongbo Liu, Yusong Zhou, Qingping Yang, Dai Wang, Mengjie Tang, Wei Liu
Frontiers in Pharmacology.2022;[Epub] CrossRef

7,406 View
244 Download
5 Web of Science
6 Crossref

Next-generation Proteomics-Based Discovery, Verification, and Validation of Urine Biomarkers for Bladder Cancer Diagnosis: Jungyo Suh, Dohyun Han, Ja Hyeon Ku, Hyeon Hoe Kim, Cheol Kwak, Chang Wook Jeong; Cancer Res Treat. 2022;54(3):882-893. Published online October 9, 2021; DOI: https://doi.org/10.4143/crt.2021.642

Abstract PDF Supplementary Material PubReader ePub

Purpose
We aimed to identify, verify, and validate a multiplex urinary biomarker-based prediction model for diagnosis and surveillance of urothelial carcinoma of bladder, using high-throughput proteomics methods.
Materials and Methods
Label-free quantification of data-dependent and data-independent acquisition of 12 and 24 individuals was performed in each of the discovery and verification phases using mass spectrometry, simultaneously using urinary exosome and proteins. Based on five scoring system based on proteomics data and statistical methods, we selected eight proteins. Enzyme-linked immunosorbent assay on urine from 120 patients with bladder mass lesions used for validation. Using multivariable logistic regression, we selected final candidate models for predicting bladder cancer.
Results
Comparing the discovery and verification cohorts, 38% (50/132 exosomal differentially expressed proteins [DEPs]) and 44% (109/248 urinary DEPs) are consistent at statistically significance, respectively. The 20 out of 50 exosome proteins and 27 out of 109 urinary proteins were upregulated in cancer patients. From eight selected proteins, we developed two diagnostic models for bladder cancer. The area under the receiver operating characteristic curve (AUROC) of two models were 0.845 and 0.842, which outperformed AUROC of urine cytology.
Conclusion
The results showed that the two diagnostic models developed here were more accurate than urine cytology. We successfully developed and validated a multiplex urinary protein-based prediction, which will have wide applications for the rapid diagnosis of urothelial carcinoma of the bladder. External validation for this biomarker panel in large population is required.

Citations

Citations to this article as recorded by

A novel machine learning algorithm selects proteome signature to specifically identify cancer exosomes
Bingrui Li, Fernanda G Kugeratski, Raghu Kalluri
eLife.2024;[Epub] CrossRef
A novel machine learning algorithm selects proteome signature to specifically identify cancer exosomes
Bingrui Li, Fernanda G Kugeratski, Raghu Kalluri
eLife.2024;[Epub] CrossRef
Comprehensive Urinary Proteome Profiling Analysis Identifies Diagnosis and Relapse Surveillance Biomarkers for Bladder Cancer
Qi Chang, Yongqiang Chen, Jianjian Yin, Tao Wang, Yuanheng Dai, Zixin Wu, Yufeng Guo, Lingang Wang, Yufen Zhao, Hang Yuan, Dongkui Song, Lirong Zhang
Journal of Proteome Research.2024; 23(6): 2241. CrossRef
Construction of noninvasive prognostic model of bladder cancer patients based on urine proteomics and screening of natural compounds
Shun Wan, Jinlong Cao, Siyu Chen, Jianwei Yang, Huabin Wang, Chenyang Wang, Kunpeng Li, Li Yang
Journal of Cancer Research and Clinical Oncology.2023; 149(1): 281. CrossRef
Extracellular Vesicles as Potential Bladder Cancer Biomarkers: Take It or Leave It?
Ana Teixeira-Marques, Catarina Lourenço, Miguel Carlos Oliveira, Rui Henrique, Carmen Jerónimo
International Journal of Molecular Sciences.2023; 24(7): 6757. CrossRef
Advances in the application of label‐free quantitative proteomics techniques in malignancy research
Xiao Meng, Dong Liu, Yan Guan
Biomedical Chromatography.2023;[Epub] CrossRef
Off the fog to find the optimal choice: Research advances in biomarkers for early diagnosis and recurrence monitoring of bladder cancer
Jiaxin Zhao, Jinming Li, Rui Zhang
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2023; 1878(4): 188926. CrossRef
An overview of metabolomic and proteomic profiling in bipolar disorder and its clinical value
Henrique Caracho Ribeiro, Flávia da Silva Zandonadi, Alessandra Sussulini
Expert Review of Proteomics.2023; 20(11): 267. CrossRef
Proteome and immune responses of extracellular vesicles derived from macrophages infected with the periodontal pathogen Tannerella forsythia
Younggap Lim, Hyun Young Kim, Dohyun Han, Bong‐Kyu Choi
Journal of Extracellular Vesicles.2023;[Epub] CrossRef
A Liquid Biopsy in Bladder Cancer—The Current Landscape in Urinary Biomarkers
Milena Matuszczak, Adam Kiljańczyk, Maciej Salagierski
International Journal of Molecular Sciences.2022; 23(15): 8597. CrossRef
Next-generation proteomics of serum extracellular vesicles combined with single-cell RNA sequencing identifies MACROH2A1 associated with refractory COVID-19
Takahiro Kawasaki, Yoshito Takeda, Ryuya Edahiro, Yuya Shirai, Mari Nogami-Itoh, Takanori Matsuki, Hiroshi Kida, Takatoshi Enomoto, Reina Hara, Yoshimi Noda, Yuichi Adachi, Takayuki Niitsu, Saori Amiya, Yuta Yamaguchi, Teruaki Murakami, Yasuhiro Kato, Tak
Inflammation and Regeneration.2022;[Epub] CrossRef

8,103 View
279 Download
10 Web of Science
11 Crossref

The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery: Hyehyun Jeong, Kye Jin Park, Yongjune Lee, Hyung-Don Kim, Jwa Hoon Kim, Shinkyo Yoon, Bumsik Hong, Jae Lyun Lee; Cancer Res Treat. 2022;54(1):226-233. Published online May 6, 2021; DOI: https://doi.org/10.4143/crt.2021.365

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aims to evaluate the prognosis of pathologically node-positive bladder cancer after neoadjuvant chemotherapy, the role of adjuvant chemotherapy in these patients, and the value of preoperative clinical evaluation for lymph node metastases.
Materials and Methods
Patients who received neoadjuvant chemotherapy followed by partial/radical cystectomy and had pathologically confirmed lymph node metastases between January 2007 and December 2019 were identified and analyzed.
Results
A total of 53 patients were included in the study. The median age was 61 years (range, 34 to 81 years) with males comprising 86.8%. Among the 52 patients with post-neoadjuvant/pre-operative computed tomography results, only 33 patients (63.5%) were considered positive for lymph node metastasis. Sixteen patients (30.2%) received adjuvant chemotherapy (AC group), and 37 patients did not (no AC group). With the median follow-up duration of 67.7 months, the median recurrence-free survival (RFS) and the median overall survival (OS) was 8.5 months and 16.2 months, respectively. The 2-year RFS and OS rates were 23.3% and 34.6%, respectively. RFS and OS did not differ between the AC group and no AC group (median RFS, 8.8 months vs. 6.8 months, p=0.772; median OS, 16.1 months vs. 16.3 months, p=0.479). Thirty-eight patients (71.7%) experienced recurrence. Distant metastases were the dominant pattern of failure in both the AC group (91.7%) and no AC group (76.9%).
Conclusion
Patients with lymph node-positive disease after neoadjuvant chemotherapy followed by surgery showed high recurrence rates with limited survival outcomes. Little benefit was observed with the addition of adjuvant chemotherapy.

Citations

Citations to this article as recorded by

Influence of Neoadjuvant Chemotherapy on Survival Outcomes of Radical Cystectomy in Pathologically Proven Positive and Negative Lymph Nodes
Krystian Kaczmarek, Bartosz Małkiewicz, Karolina Skonieczna-Żydecka, Artur Lemiński
Cancers.2023; 15(19): 4901. CrossRef
Comparison of responses to neoadjuvant and adjuvant chemotherapies in muscle-invasive bladder cancer
Serhat Sekmek, Gökhan Ucar, Irfan Karahan, Dogan Bayram, Selin Aktürk Esen, Ismet Seven, Mehmet Ali Nahit Sendur, Dogan Uncu
African Journal of Urology.2023;[Epub] CrossRef

5,298 View
181 Download
3 Web of Science
2 Crossref

Gastrointestinal cancer

High Systemic Inflammation Response Index (SIRI) Indicates Poor Outcome in Gallbladder Cancer Patients with Surgical Resection: A Single Institution Experience in China: Lejia Sun, Wenmo Hu, Meixi Liu, Yang Chen, Bao Jin, Haifeng Xu, Shunda Du, Yiyao Xu, Haitao Zhao, Xin Lu, Xinting Sang, Shouxian Zhong, Huayu Yang, Yilei Mao; Cancer Res Treat. 2020;52(4):1199-1210. Published online July 21, 2020; DOI: https://doi.org/10.4143/crt.2020.303

Abstract PDF PubReader ePub

Purpose
The systemic inflammation response index (SIRI) has been reported to have prognostic ability in various solid tumors but has not been studied in gallbladder cancer (GBC). We aimed to determine its prognostic value in GBC.
Materials and Methods
From 2003 to 2017, patients with confirmed GBC were recruited. To determine the SIRI’s optimal cutoff value, a time-dependent receiver operating characteristic curve was applied. Univariate and multivariate Cox analyses were performed for the recognition of significant factors. Then the cohort was randomly divided into the training and the validation set. A nomogram was constructed using the SIRI and other selected indicators in the training set, and compared with the TNM staging system. C-index, calibration plots, and decision curve analysis were performed to assess the nomogram’s clinical utility.
Results
One hundred twenty-four patients were included. The SIRI’s optimal cutoff value divided patients into high (≥ 0.89) and low SIRI (< 0.89) groups. Kaplan-Meier curves according to SIRI levels were significantly different (p < 0.001). The high SIRI group tended to stay longer in hospital and lost more blood during surgery. SIRI, body mass index, weight loss, carbohydrate antigen 19-9, radical surgery, and TNM stage were combined to generate a nomogram (C-index, 0.821 in the training cohort, 0.828 in the validation cohort) that was significantly superior to the TNM staging system both in the training (C-index, 0.655) and validation cohort (C-index, 0.649).
Conclusion
The SIRI is an independent predictor of prognosis in GBC. A nomogram based on the SIRI may help physicians to precisely stratify patients and implement individualized treatment.

Citations

Citations to this article as recorded by

Combining systemic inflammatory response index and albumin fibrinogen ratio to predict early serious complications and prognosis after resectable gastric cancer
Jing-Yao Ren, Da Wang, Li-Hui Zhu, Shuo Liu, Miao Yu, Hui Cai
World Journal of Gastrointestinal Oncology.2024; 16(3): 732. CrossRef
Association of Systemic Inflammation Response Index with Short-Term All-Cause Mortality in Decompensated Liver Cirrhosis Patients
Jin Cheng, Honglei Ju, Guixiang Wang, Chiyi He, Wei Wang
Journal of Inflammation Research.2024; Volume 17: 8985. CrossRef
The role of systemic inflammatory response index (SIRI) and tumor-infiltrating lymphocytes (TILs) in the prognosis of patients with laryngeal squamous cell carcinoma
Tian Wang, Duo Zhang, Di Tang, Yu Heng, Li-ming Lu, Lei Tao
Journal of Cancer Research and Clinical Oncology.2023; 149(9): 5627. CrossRef
Preoperative Fibrinogen Albumin Ratio is an Effective Biomarker for Prognostic Evaluation of Gallbladder Carcinoma After Radical Resection: A 10-Year Retrospective Study at a Single Center
Qi Li, Jian Zhang, Qi Gao, Jialu Fu, Mengke Li, Hengchao Liu, Chen Chen, Dong Zhang, Zhimin Geng
Journal of Inflammation Research.2023; Volume 16: 677. CrossRef
Preoperative systemic inflammatory response index predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation
Songping Cui, Shuang Cao, Qing Chen, Qiang He, Ren Lang
Frontiers in Immunology.2023;[Epub] CrossRef
Assessment of aggregate index of systemic inflammation and systemic inflammatory response index in dry age-related macular degeneration: a retrospective study
Naif S. Sannan
Frontiers in Medicine.2023;[Epub] CrossRef
Value of preoperative systemic inflammatory response index and prognostic nutritional index in predicting prognosis of patients with superficial esophageal squamous cell carcinoma
Jing Wang, Xue-Li Ding, Zi-Bin Tian
World Chinese Journal of Digestology.2023; 31(9): 369. CrossRef
The Prognostic Value and Potential Mechanism of Tumor-Nutrition-Inflammation Index and Genes in Patients with Advanced Lung Cancer
Huan Wang, Yuting Shi, Yueli Shi, Mengqing Cao, Long Zhang, Yuan Wu, Yun Xu, Kai Wang, Xianwu Weng, Bing Niu
International Journal of Clinical Practice.2023; 2023: 1. CrossRef
The Potential Value of Systemic Inflammation Response Index on Delirium After Hip Arthroplasty Surgery in Older Patients: A Retrospective Study
Wenbin Lu, Shengwei Lin, Cheng Wang, Peipei Jin, Jinjun Bian
International Journal of General Medicine.2023; Volume 16: 5355. CrossRef
Systemic Inflammation Response Index (SIRI) Independently Predicts Survival in Advanced Lung Adenocarcinoma Patients Treated with First-Generation EGFR-TKIs
Shun Jiang, Sisi Wang, Qianqian Wang, Chao Deng, Yuhua Feng, Fang Ma, Jin'an Ma, Xianling Liu, Chunhong Hu, Tao Hou
Cancer Management and Research.2021; Volume 13: 1315. CrossRef
The Prognostic Value of Preoperative Systemic Inflammatory Response Index (SIRI) in Patients With High-Grade Glioma and the Establishment of a Nomogram
Qian He, Longhao Li, Qinglan Ren
Frontiers in Oncology.2021;[Epub] CrossRef
Prognostic Value of Inflammatory Biomarkers in Patients With Stage I Lung Adenocarcinoma Treated With Surgical Dissection
Yu-Jia Shen, Li-Qiang Qian, Zheng-Ping Ding, Qing-Quan Luo, Heng Zhao, Wu-Yan Xia, Yuan-Yuan Fu, Wen Feng, Qin Zhang, Wen Yu, Xu-Wei Cai, Xiao-Long Fu
Frontiers in Oncology.2021;[Epub] CrossRef

8,887 View
114 Download
26 Web of Science
12 Crossref

Case Report

Seminal Vesicle Involvement by Carcinoma In Situ of the Bladder: Clonal Analysis Using Next-Generation Sequencing to Elucidate the Mechanism of Tumor Spread: Hyun Sik Park, Hyun Bin Shin, Myung-Shin Lee, Joo Heon Kim, Seon-Young Kim, Jinsung Park; Cancer Res Treat. 2020;52(4):1283-1287. Published online March 19, 2020; DOI: https://doi.org/10.4143/crt.2020.002

Abstract PDF Supplementary Material PubReader ePub: We present a rare case of urothelial carcinoma in situ (CIS), which invades the prostate and seminal vesicle (SV). A 70-year-old man underwent transurethral resection of bladder (TURB), and the pathologic examination revealed multiple CIS. Although the patient received intravesical bacillus Calmette-Guerin (BCG) therapy following TURB, recurrence of CIS was confirmed in the bladder and left distal ureter at 3 months following BCG. Radical cystectomy was performed due to BCG-refractory CIS. Microscopically, CIS was found throughout the mucosa of the bladder, left ureter, prostatic duct, and both SVs. Next-generation sequencing revealed significant differences in tumor clonality between bladder and SV CIS cells. Among 101 (bladder CIS) and 95 (SV CIS) somatic mutations, only two were shared, and only one gene (ARHGAP23) was common exon coding region gene. In conclusion, multicentric genetic changes, in line with the field-cancerization effect, may result in SV involvement by CIS of the bladder.

5,427 View
137 Download

Original Articles

Oncologic, Perioperative Outcomes of Female Radical Cystectomy: Results from a Multicenter Study in Korea: Ji Sung Shim, Ho Kyung Seo, Ja Hyeon Ku, Byong Chang Jeong, Bumsik Hong, Seok Ho Kang, UCART (Urothelial Cancer-Advanced Research and Treatment Group in Korea) Group; Cancer Res Treat. 2019;51(3):1064-1072. Published online October 30, 2018; DOI: https://doi.org/10.4143/crt.2018.515

Abstract PDF PubReader ePub

Purpose
The lower incidence of bladder cancer among women has led to a lack of information on female radical cystectomy (RC). This study aimed to analyze the characteristics related with female RC in a cohort from multiple academic institutions.
Materials and Methods
This was a retrospective review of 384 female patients who underwent RC for bladder cancer. Epidemiologic, perioperative variables including urologic referral periodwith consequent pathologic stage distributions were assessed. The changes in surgical techniques over time were illustrated. Also, we evaluated recurrence-free survival (RFS) at 2 and 5 years and overall survival (OS) at 5 years with stage-specific analyses using the Kaplan-Meier method.
Results
The mean follow-up time was 35 months (interquartile rage [IQR], 9 to 55). The average time to urologic referral with initial symptoms was 5.5 (IQR, 1 to 6) months and over 20% of patients visited clinics after 6 months. In subsequent stage distributions according to referral period, T2 or higher stage distributions were abruptly increased after 1 year. Overall 2-year/5-year RFS rates were 0.72/0.57 and 5-year OS was 0.61. Notable surgical descriptions were as follows: 91% of patients underwent open RC; 80% of patients underwent an ileal conduit; and 83% of patients received anterior exenteration. However, the proportions of robotic surgery, orthotopic neobladder and organ sparing cystectomy have increased recen-tly.
Conclusion
We identified the general characteristics and changes in pattern of female RC. Our results also suggest that women are susceptible to delays in referral to an urologist and are at greater risk for worse prognosis.

Citations

Citations to this article as recorded by

Perioperative, oncological, and survival outcomes of robotic radical cystectomy with urinary diversion in females
Varun V. Agarwal, B. Yuvaraja Thyavihally, Santosh Subhash Waigankar, Preetham Dev, Abhinav P. Pednekar, Diptiman Roy, Nevitha Athikari, Meenal Hastak, Naresh Badlani, D. Harshwardhan Pokharkar, Nagaraja Sekhar Ayyalasomayajula, Archan Khandekar, Ashish A
Indian Journal of Urology.2023; 39(1): 27. CrossRef
Safety and Efficacy of Reproductive Organ-Sparing Radical Cystectomy in Women With Variant Histology and Advanced Stage
Sunil H. Patel, Shirley Wang, Meredith R. Metcalf, Natasha Gupta, Andrew Gabrielson, Esther Lee, Mary Rostom, Phil Pierorazio, Armine Smith, Noah Hahn, Mark Schoenberg, Max Kates, Jean Hoffman-Censits, Trinity J. Bivalacqua
Clinical Genitourinary Cancer.2022; 20(1): 60. CrossRef
The learning curve for robot-assisted radical cystectomy with total intracorporeal urinary diversion based on radical cystectomy pentafecta
Tae Il Noh, Ji Sung Shim, Sung Gu Kang, Jun Cheon, Jong Hyun Pyun, Seok Ho Kang
Frontiers in Oncology.2022;[Epub] CrossRef

6,798 View
144 Download
3 Web of Science
3 Crossref

Health-Related Quality of Life, Perceived Social Support, and Depression in Disease-Free Survivors Who Underwent Curative Surgery Only for Prostate, Kidney and Bladder Cancer: Comparison among Survivors and with the General Population: Dong Wook Shin, Hyun Sik Park, Sang Hyub Lee, Seung Hyun Jeon, Seok Cho, Seok Ho Kang, Seung Chol Park, Jong Hyock Park, Jinsung Park; Cancer Res Treat. 2019;51(1):289-299. Published online May 4, 2018; DOI: https://doi.org/10.4143/crt.2018.053

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to compare health-related quality of life (HRQoL) of disease-free prostate (PC), kidney (KC), and bladder cancer (BC) survivors with that of the general population.
Materials and Methods
Our study included 331 urological cancer (UC) survivors (114 PC, 108 KC, and 109 BC) aged ≥ 50 years disease-free for at least 1 year after surgery. The control group included 1,177 subjects without a history of cancer. The HRQoL was assessed using the European Organization for Research and Treatment of Cancer QLQ-C30, the Duke-UNC Functional Social Support Questionnaire, and the Patient Health Questionnaire-9.
Results
There was no significant difference between the groups in terms of any of the functioning sub-scales and symptoms, except significantly lower social functioning observed in BC survivors than that observed in KC survivors. Although the three groups of UC survivors showed essentially similar functioning sub-scales and symptoms when compared to the general population, PC and BC survivors showed significantly lower social functioning and a lower appetite than that observed in controls. KC survivors showed lower physical functioning, as well as higher pain and dyspnea. Although all three groups of UC survivors reported higher financial difficulties, they also reported higher perceived social support than that reported by the non-cancer control group. No statistically significant difference was observed in terms of depressive symptoms between each group of UC survivors and the general population.
Conclusion
Disease-free survivors of the three major types of UCs showed generally similar HRQoL compared to the general population, as well as compared to each other.

Citations

Citations to this article as recorded by

Role performance and factors affecting quality of life in bladder cancer survivors with ileal orthotopic neobladder
So Hee Kim, Eunjung Ryu, Byong Chang Jeong
Asia-Pacific Journal of Oncology Nursing.2024; 11(6): 100490. CrossRef
The mental and emotional status after radical cystectomy and different urinary diversion orthotopic bladder substitution versus external urinary diversion after radical cystectomy: A propensity score‐matched study
Giuseppe Palermo, Francesco Pio Bizzarri, Eros Scarciglia, Emilio Sacco, Koosha Moosavi Seyed, Pierluigi Russo, Filippo Gavi, Battista Filomena Giovanni, Francesco Rossi, Marco Campetella, Angelo Totaro, Nazario Foschi, Marco Racioppi
International Journal of Urology.2024;[Epub] CrossRef
Properties of the Shift and Persist Questionnaire in adolescent and young adult cancer patients and survivors: Validity, consistency, and interpretability
Karly M. Murphy, Edith Chen, Edward H. Ip, Abby R. Rosenberg, Mallory A. Snyder, John M. Salsman
Quality of Life Research.2023; 32(1): 273. CrossRef
Adoption of patient communication rules in clinical practice and the role of faith-based communities in shaping them: the palliative aspect of spiritual support
Konstantin Sokolovskiy, Olga Pashanova, Vladimir Beketov, Andrey Aleshkin
Mental Health, Religion & Culture.2023; 26(1): 16. CrossRef
Identifying the unmet supportive care needs of people affected by kidney cancer: a systematic review
Amy O’Dea, Craig Gedye, Belinda Jago, Catherine Paterson
Journal of Cancer Survivorship.2022; 16(6): 1279. CrossRef
Mental Health in Urologic Oncology
Danyon Anderson, Abrahim N. Razzak, Matthew McDonald, David Cao, Jamal Hasoon, Omar Viswanath, Alan D. Kaye, Ivan Urits
Health Psychology Research.2022;[Epub] CrossRef
Psychological Distress in Patients Treated for Renal Cell Carcinoma: A Systematic Literature Review
Liliana Vartolomei, Manuela Schmidinger, Mihai Vartolomei, Shahrokh Shariat
Journal of Clinical Medicine.2022; 11(21): 6383. CrossRef
Health-Related Quality of Life among Cancer Survivors Depending on the Occupational Status
Kisook Kim, Hyohyeon Yoon
International Journal of Environmental Research and Public Health.2021; 18(7): 3803. CrossRef
Feasibility of a socio-spiritual intervention to improve quality of life of adult Nigerians with cancer and their family caregivers: Protocol for a randomised controlled trial
Israel Gabriel, Debra Creedy, Elisabeth Coyne
Contemporary Clinical Trials Communications.2021; 22: 100802. CrossRef
Age-specific health-related quality of life in disease-free long-term prostate cancer survivors versus male population controls—results from a population-based study
Salome Adam, Daniela Doege, Lena Koch-Gallenkamp, Melissa S. Y. Thong, Heike Bertram, Andrea Eberle, Bernd Holleczek, Ron Pritzkuleit, Mechthild Waldeyer-Sauerland, Annika Waldmann, Sylke Ruth Zeissig, Lina Jansen, Sabine Rohrmann, Hermann Brenner, Volker
Supportive Care in Cancer.2020; 28(6): 2875. CrossRef
Comorbid depression in medical diseases
Stefan M. Gold, Ole Köhler-Forsberg, Rona Moss-Morris, Anja Mehnert, J. Jaime Miranda, Monika Bullinger, Andrew Steptoe, Mary A. Whooley, Christian Otte
Nature Reviews Disease Primers.2020;[Epub] CrossRef
Health-related Quality of Life and Its Related Factors among Cancer Survivors and General Adults: Focusing on Lifestyle Behaviors and Mental Health
Eun A Song, Youngran Kweon, Yoon Young Hwang, Minjeong An
Korean Journal of Adult Nursing.2020; 32(4): 385. CrossRef
Age and gender differences in anxiety and depression in cancer patients compared with the general population
Andreas Hinz, Philipp Yorck Herzberg, Florian Lordick, Joachim Weis, Hermann Faller, Elmar Brähler, Martin Härter, Karl Wegscheider, Kristina Geue, Anja Mehnert
European Journal of Cancer Care.2019;[Epub] CrossRef

11,986 View
214 Download
12 Web of Science
13 Crossref

Trends in Gallbladder Cancer Incidence and Survival in Korea: Youngjun Wi, Hyeongtaek Woo, Young-Joo Won, Jin-Young Jang, Aesun Shin; Cancer Res Treat. 2018;50(4):1444-1451. Published online January 24, 2018; DOI: https://doi.org/10.4143/crt.2017.279

Abstract PDF Supplementary Material PubReader ePub

Purpose
The current study was undertaken to examine the trend in gallbladder cancer (GBC) incidence and survival in Korea.
Materials and Methods
GBC incidence data by histologic typewere obtained from the Korea Central Cancer Registry. Age-standardized incidence rates were calculated using the mid-year Korean population of 2000 as a standard population, and a joinpoint regression model was used to calculate the annual percent change (APC) in incidence rates. Incidence by Surveillance, Epidemiology and End Results (SEER) summary stage and by geographical areas and female-to-male incidence rate ratios was also described.
Results
The number of new GBC cases increased between 1999 and 2013. Nevertheless, the agestandardized incidence rate decreased by 0.5% per year in men (p < 0.01), whereas the incidence rate in women did not change significantly over the same period (APC, –0.2; p=0.6). The most common histologic type was adenocarcinoma in both sexes. Based on the SEER stage, the distant stage was the most frequent stage (41%), followed by the regional stage (37%). Ulsan (4.31/100,000 for men and 4.09/100,000 forwomen in 2009- 2013) and Gyeongsangnam-do (4.15/100,000 for men and 3.54/100,000 for women) showed the highest GBC incidence, whereas the lowest incidence was observed in Seoul and Gyeonggi-do. There were no significant sex differences in the incidence of GBC (femaleto-male incidence rate ratio, 0.96).
Conclusion
The overall incidence of GBC in Korea did not change significantly over the 15-year period. Incidence for men and women was similar. However, geographical variation was found.

Citations

Citations to this article as recorded by

Viscum album, as alternative and bridge to palliative chemotherapy in recurrent gallbladder cancer following laparoscopic radical cholecystectomy: a case report
Joonggyeong Shin, Eunsang Yim, Chang Moo Kang
Korean Journal of Clinical Oncology.2024; 19(2): 88. CrossRef
Association of female reproductive and hormonal factors with gallbladder cancer risk in Asia: A pooled analysis of the Asia Cohort Consortium
Aesun Shin, Sooyoung Cho, Sarah Krull Abe, Md Rashedul Islam, Md Shafiur Rahman, Eiko Saito, Sayada Zartasha Kazmi, Ryoko Katagiri, Melissa Merritt, Ji‐Yeob Choi, Xiao‐Ou Shu, Norie Sawada, Akiko Tamakoshi, Woon‐Puay Koh, Ritsu Sakata, Atsushi Hozawa, Jeo
International Journal of Cancer.2024; 155(2): 240. CrossRef
Establishment of a chronic biliary disease mouse model with cholecystoduodenal anastomosis for intestinal microbiome preservation
Yunseon Jang, Jung Yeon Kim, Song Yeon Han, Arum Park, So Jeong Baek, Gyurim Lee, Jihee Kang, Hyewon Ryu, Seok-Hwan Kim
World Journal of Gastroenterology.2024; 30(46): 4937. CrossRef
Lessons learnt from 1300 consecutive gallbladder cancer surgeries: Evolving role of peri-operative chemotherapy in the treatment paradigm
Shraddha Patkar, Swapnil Patel, Amit Gupta, Vikas Ostwal, Anant Ramaswamy, Nitin Shetty, Mahesh Goel
European Journal of Surgical Oncology.2023; 49(10): 107035. CrossRef
Clinicopathologic significance of the delta-like ligand 4, vascular endothelial growth factor, and hypoxia-inducible factor-2α in gallbladder cancer
Sujin Park, Junsik Kim, Woncheol Jang, Kyoung-Mee Kim, Kee-Taek Jang
Journal of Pathology and Translational Medicine.2023; 57(2): 113. CrossRef
Radical surgery for stage IV gallbladder cancers: Treatment strategies in patients with limited metastatic burden
Shraddha Patkar, Swapnil Patel, Mufaddal Kazi, Mahesh Goel
Annals of Hepato-Biliary-Pancreatic Surgery.2023; 27(2): 180. CrossRef
EGFR-targeted fluorescent imaging using the da Vinci® Firefly™ camera for gallbladder cancer
Jung Ha Choi, Chang Moo Kang, Jeong Youp Park
World Journal of Surgical Oncology.2022;[Epub] CrossRef
Publication Trends of Research on Gallbladder Cancer During 2001–2021: A 20-Year Bibliometric Analysis
Wentao Sun, Wenze Wan, Zhihui Gao, Tao Suo, Sheng Shen, Houbao Liu
Frontiers in Oncology.2022;[Epub] CrossRef
A Case Report of Symptom Improvement with Recurrent Gallbladder Cancer Patients Treated with Korean Medicine-based Integrative Cancer Treatment
Eun-ju Ko, Sung-kuk Do, Ji-hye Park, Si-yeon Song, Yeon-weol Lee, Hwa-seung Yoo
The Journal of Internal Korean Medicine.2022; 43(3): 477. CrossRef
Target nursing care on anxiety and depression in patients with gallbladder cancer during perioperative period
Shuang Liu, Li Zhang, Xiu-e Guan, Lei Zhang, Rui Wang
Medicine.2022; 101(31): e29883. CrossRef
Epidemiological trends of gallbladder cancer in Australia between 1982 to 2018: A population-based study utilizing the Australian Cancer Database
Taha Mollah, Marc Chia, Luke C. Wang, Prasenjit Modak, Kirby R. Qin
Annals of Hepato-Biliary-Pancreatic Surgery.2022; 26(3): 263. CrossRef
A nomogram for predicting cancer-specific survival for elderly patients with gallbladder cancer
Chong Wen, Jie Tang, Tao Wang, Hao Luo
BMC Gastroenterology.2022;[Epub] CrossRef
Incidence and Preoperative Predictor Factors of Gallbladder Cancer Before Laparoscopic Cholecystectomy: a Systematic Review
Tarek Kellil, Mohamed Ali Chaouch, Emna Aloui, Mohamed Amine Tormane, Sahbi Khaled Taieb, Faouzi Noomen, Khadija Zouari
Journal of Gastrointestinal Cancer.2021; 52(1): 68. CrossRef
Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin
Hyehyun Jeong, Jae Ho Jeong, Kyu-Pyo Kim, Sang Soo Lee, Dong Wook Oh, Do Hyun Park, Tae Jun Song, Yangsoon Park, Seung-Mo Hong, Baek-Yeol Ryoo, Changhoon Yoo
Cancers.2021; 13(2): 161. CrossRef
Tenascin-W Is a Novel Stromal Marker in Biliary Tract Cancers
Ismaïl Hendaoui, Ahlem Lahmar, Luca Campo, Sihem Mebarki, Sandrine Bichet, Daniel Hess, Martin Degen, Nidhameddine Kchir, Leila Charrada-Ben Farhat, Rania Hefaiedh, Christian Ruiz, Luigi M. Terracciano, Richard P. Tucker, Lotfi Hendaoui, Ruth Chiquet-Ehri
Frontiers in Immunology.2021;[Epub] CrossRef
An overview on possible links between aflatoxin B1 exposure and gallbladder cancer
Jéssica Costa, Nelson Lima, Cledir Santos
Mycotoxin Research.2021; 37(3): 205. CrossRef
Gender Difference in Gallbladder Cancer: Focusing on the Clinical Characteristics, Treatment, and Prognosis of Korean Patients
Eui Joo Kim
The Korean Journal of Gastroenterology.2021; 78(1): 27. CrossRef
Urban-rural disparity in cancer mortality and changing trend in Tianjin, China, during 1999 and 2016
Wenlong Zheng, Hui Zhang, Dezheng Wang, Chong Wang, Shuang Zhang, Chengfeng Shen, Wei Li, Guohong Jiang
BMC Cancer.2021;[Epub] CrossRef
Spatial epidemiologic analysis of the liver cancer and gallbladder cancer incidence and its determinants in South Korea
Jieun Jang, Dae-Sung Yoo, Byung Chul Chun
BMC Public Health.2021;[Epub] CrossRef
Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer
Ji Hye Kim, Kyungbin Kim, Misung Kim, Young Min Kim, Jae Hee Suh, Hee Jeong Cha, Hye Jeong Choi
Journal of Pathology and Translational Medicine.2020; 54(2): 154. CrossRef
Genetic landscape of gallbladder cancer: Global overview
Ravi Mehrotra, Sonam Tulsyan, Showket Hussain, Balraj Mittal, Sundeep Singh Saluja, Sandeep Singh, Pranay Tanwar, Asiya Khan, Milind Javle, Manal M. Hassan, Shubham Pant, Xabier De Aretxabala, Bhawna Sirohi, Preetha Rajaraman, Tanvir Kaur, G.K. Rath
Mutation Research/Reviews in Mutation Research.2018; 778: 61. CrossRef

9,636 View
245 Download
18 Web of Science
21 Crossref

Development and Validation of the Korean Version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients with Non-muscle Invasive Bladder Cancer: EORTC QLQ-NMIBC24: Jinsung Park, Dong Wook Shin, Tae-Hwan Kim, Seung Il Jung, Jong Kil Nam, Seung Chol Park, Sungwoo Hong, Jae Hung Jung, Hongwook Kim, Won Tae Kim; Cancer Res Treat. 2018;50(1):40-49. Published online March 10, 2017; DOI: https://doi.org/10.4143/crt.2016.594

Abstract PDF PubReader ePub

Purpose
We aimed to evaluate psychometric properties of the Korean version of the EORTC QLQ-NMIBC24 when applied to Korean non-muscle invasive bladder cancer (NMIBC) patients.
Materials and Methods
A total of 249 patients who underwent curative transurethral resection of bladder tumor (TURBT) for primary orrecurrentNMIBCwere asked to complete theKorean version of EORTC QLQ-C30 and -NMIBC24 questionnaires three times (preoperative, post-TURBT 3 months and 6 months). Linguistic validation and psychometric evaluation of the questionnaire was conducted.
Results
Multitrait scaling analysis confirmed satisfactory construct validity in five scales except the malaise scale. Internal consistency was good (Cronbach’s alpha ≥ 0.70) for the five scales except the malaise scale at the all three time points. Known-group comparison analyses showed better quality-of-life (QOL) scores in patients with higher performance status as expected, and better sexual function in men than women (p < 0.05). Most of the scales had low correlations (< 0.40) with the scales in QLQ-C30 showing divergent validity, except for malaise scale which showed higher correlations (0.42 to 0.60). Responsiveness to change was consistent with clinical implications over time after TURBT.
Conclusion
The Korean version of the EORTC QLQ-NMIBC24 has good reliability and cross-cultural validity for measuring various QOL aspects that can be self-administered to Korean NMIBC patients undergoing TURBT.

Citations

Citations to this article as recorded by

Health-related Quality of Life During the First 4 Years After Non–Muscle-invasive Bladder Cancer Diagnosis: Results of a Large Multicentre Prospective Cohort
Ivy Beeren, Nena E. Klerks, Katja K. Aben, Jorg R. Oddens, J. Alfred Witjes, Lambertus A. Kiemeney, Alina Vrieling
European Urology Oncology.2024; 7(4): 829. CrossRef
The current use of the EORTC QLQ-NMIBC24 and QLQ-BLM30 questionnaires for the assessment of health-related quality of life in bladder cancer patients: a systematic review
E. Rammant, L. Fox, K. Beyer, N. K. Aaronson, R. Chaloner, S. De Padova, F. Liedberg, L. M. Wintner, K. Decaestecker, V. Fonteyne, N. Perdek, H. Wylie, J. W. F. Catto, T. M. Ripping, B. Holzner, M. Van Leeuwen, M. Van Hemelrijck
Quality of Life Research.2023; 32(8): 2127. CrossRef
Quality of life in bladder cancer: systematic review and meta-analysis
Sima Rafiei, Golnaz Kheradkhah, Grigorios Kotronoulas, Maryam Doustmehraban, Farnoosh Shafiei, Maryam Masoumi, Elaheh Parnian, Elmira Nosrati Sanjabad, Ahmad Ghashghaee
BMJ Supportive & Palliative Care.2023; 13(e3): e707. CrossRef
Quality of life patterns and its association with predictors among non-muscle invasive bladder cancer survivors: A latent profile analysis
Jeongok Park, Young Deuk Choi, Kyoungjin Lee, Miae Seo, Ahyoung Cho, Sejeong Lee, Keum-hee Nam
Asia-Pacific Journal of Oncology Nursing.2022; 9(6): 100063. CrossRef
Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer
T. M. Ripping, E. Rammant, J. A. Witjes, N. K. Aaronson, M. van Hemelrijck, L. M. C. van Hoogstraten, J. Boormans, C. A. Goossens, A. G. van der Heijden, M. C. C. M. Hulshof, G. J. L. H. van Leenders, A. M. van Leliveld, R. P. Meijer, R. J. A. van Moorsel
Health and Quality of Life Outcomes.2022;[Epub] CrossRef
Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer
Theodora M. Ripping, Ellen Westhoff, Neil K. Aaronson, Mieke Van Hemelrijck, Elke Rammant, J. Alfred Witjes, Lambertus. A. Kiemeney, Katja K. H. Aben, Alina Vrieling
Journal of Patient-Reported Outcomes.2021;[Epub] CrossRef
Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews

Lauren J Lee, Christina S Kwon, Anna Forsythe, Carla M Mamolo, Elizabeth T Masters, Ira A Jacobs
ClinicoEconomics and Outcomes Research.2020; Volume 12: 693. CrossRef
Effect of a patient education and rehabilitation program on anxiety, depression and quality of life in muscle invasive bladder cancer patients treated with adjuvant chemotherapy
Zhonghui Li, Dan Wei, Chenxi Zhu, Qing Zhang
Medicine.2019; 98(44): e17437. CrossRef

8,863 View
302 Download
13 Web of Science
8 Crossref

TRIM29 Overexpression Promotes Proliferation and Survival of Bladder Cancer Cells through NF-κB Signaling: Shu-Tao Tan, Sheng-Ye Liu, Bin Wu; Cancer Res Treat. 2016;48(4):1302-1312. Published online March 11, 2016; DOI: https://doi.org/10.4143/crt.2015.381

Abstract PDF PubReader ePub

Purpose
TRIM29 overexpression has been reported in several human malignancies and showed correlation with cancer cell malignancy. The aim of the current study is to examine its clinical significance and biological roles in human bladder cancer tissues and cell lines. Materials and Methods A total of 102 cases of bladder cancer tissues were examined for TRIM29 expression by immunohistochemistry. siRNA and plasmid transfection were performed in 5637 and BIU- 87 cell lines. Cell Counting Kit-8, flow cytometry, western blot, and real-time polymerase chain reaction were performed to examine its biological roles and mechanism in bladder cancer cells.
Results
We found that TRIM29 overexpression showed correlation with invading depth (p=0.0087). Knockdown of TRIM29 expression in bladder cancer cell line 5637 inhibited cell growth rate and cell cycle transition while its overexpression in BIU-87 cells accelerated cell proliferation and cell cycle progression. TRIM29 overexpression also inhibited cell apoptosis induced by cisplatin. In addition, we demonstrated that TRIM29 depletion decreased while its overexpression led to upregulated expression of cyclin D1, cyclin E, and Bcl-2. We also showed that TRIM29 knockdown inhibited protein kinase C (PKC) and nuclear factor κB (NF-κB) signaling while its overexpression stimulated the PKC and NF-κB pathways. BAY 11-7082 (NF-κB inhibitor) partly attenuated the effect of TRIM29 on expression of cyclin and Bcl-2. Treatment with PKC inhibitor staurosporine resulted in ameliorated TRIM29 induced activation of NF-κB. Conclusion The current study demonstrated that TRIM29 upregulates cyclin and Bcl family proteins level to facilitate malignant cell growth and inhibit drug-induced apoptosis in bladder cancer, possibly through PKC–NF-κB signaling pathways.

Citations

Citations to this article as recorded by

Lactate dehydrogenase A promotes nasopharyngeal carcinoma progression through the TAK1/NF-κB Axis
Yingzi Li, Lanfang Chen, Qiaochong Zheng, Guanxin Liu, Mengjiao Wang, Shupei Wei, Tao Chen
Molecular Biology Reports.2024;[Epub] CrossRef
Silencing TRIM29 Sensitizes Non-small Cell Lung Cancer Cells to Anlotinib by Promoting Apoptosis via Binding RAD50
Min Wu, Meng-Meng Jin, Xiao-Hui Cao, Lei Zhao, Yong-Huai Li
Current Cancer Drug Targets.2024; 24(4): 445. CrossRef
20-hydroxyecdysone suppresses bladder cancer progression via inhibiting USP21: A mechanism associated with deubiquitination and degradation of p65
Qiang Ma, Fei Wu, Xiaohui Liu, Cuifang Zhao, Yang Sun, Yuanyuan Li, Wei Zhang, Hongge Ju, Yukun Wang
Translational Oncology.2024; 45: 101958. CrossRef
Intricate confrontation: Research progress and application potential of TRIM family proteins in tumor immune escape
Junjie Gu, Jingyi Chen, Shuaixi Xiang, Xikun Zhou, Jing Li
Journal of Advanced Research.2023; 54: 147. CrossRef
TRIM29 promotes podocyte pyroptosis in diabetic nephropathy through the NF‐kB/NLRP3 inflammasome pathway
Xiaohong Xu, Zihan Qin, Ce Zhang, Xia Mi, Chi Zhang, Feihong Zhou, Junsheng Wang, Liexiang Zhang, Fei Hua
Cell Biology International.2023; 47(6): 1126. CrossRef
Potential implications of protein kinase Cα in pathophysiological conditions and therapeutic interventions
Rishi Kant Singh, Sanjay Kumar, Sandeep Kumar, Alok Shukla, Naveen Kumar, Anand Kumar Patel, Lokesh Kumar Yadav, Kaushalendra, Meera Antiwal, Arbind Acharya
Life Sciences.2023; 330: 121999. CrossRef
TRIM29 promotes the progression of colorectal cancer by suppressing EZH2 degradation
Yuanjian Chen, Jun Ma, Mingming Zhang
Experimental Biology and Medicine.2023; 248(18): 1527. CrossRef
TRIM14 and TRIM29 as potential tumor markers for breast cancer diagnosis
Mohammadreza Roshanazadeh, mojtaba rashidi, Arash sanaei, Hossein azizi dariuni, amirnader emami razavi, Maryam Adelipour
Journal of Breast Disease.2023; 16(4): 4. CrossRef
TRIM29 regulates the SETBP1/SET/PP2A axis via transcription factor VEZF1 to promote progression of ovarian cancer
Huai-Yu Qiao, Qi Zhang, Jia-Mei Wang, Jing-Yi Jiang, Ling-Yue Huyan, Jing Yan, Chao Li, Hua-Qin Wang
Cancer Letters.2022; 529: 85. CrossRef
NCAPG promotes tumorigenesis of bladder cancer through NF-κB signaling pathway
Feng Tang, Hua Yu, Xia Wang, Jiageng Shi, Zhizhuang Chen, Hao Wang, Ziyu Wan, Qiqi Fu, Xuan Hu, Yisha Zuhaer, Tao Liu, Zhonghua Yang, Jianping Peng
Biochemical and Biophysical Research Communications.2022; 622: 101. CrossRef
Tripartite Motif Containing 26 is a Positive Predictor for Endometrial Carcinoma Patients and Regulates Cell Survival in Endometrial Carcinoma
Tanmin Lu, Yu Wu
Hormone and Metabolic Research.2022; 54(12): 859. CrossRef
TRIM3 and TRIM16 as potential tumor suppressors in breast cancer patients
Mohammad Reza Roshanazadeh, Maryam Adelipour, Arash Sanaei, Hadi Chenane, Mojtaba Rashidi
BMC Research Notes.2022;[Epub] CrossRef
Protein Kinase C (PKC) Isozymes as Diagnostic and Prognostic Biomarkers and Therapeutic Targets for Cancer
Takahito Kawano, Junichi Inokuchi, Masatoshi Eto, Masaharu Murata, Jeong-Hun Kang
Cancers.2022; 14(21): 5425. CrossRef
Transcriptional dysregulation of TRIM29 promotes colorectal cancer carcinogenesis via pyruvate kinase-mediated glucose metabolism
Jing Han, Zitong Zhao, Nan Zhang, Yang Yang, Liying Ma, Li Feng, Xue Zhang, Jing Zuo, Zhisong Fan, Yudong Wang, Yongmei Song, Guiying Wang
Aging.2021; 13(4): 5034. CrossRef
E3 ubiquitin ligase TRIM29 promotes pancreatic cancer growth and progression via stabilizing Yes-associated protein 1
Xueqiang Deng, Xiaowei Fu, Hong Teng, Lu Fang, Bo Liang, Rengui Zeng, Lian Chen, Yeqing Zou
Journal of Translational Medicine.2021;[Epub] CrossRef
Potential Immune Biomarker Candidates and Immune Subtypes of Lung Adenocarcinoma for Developing mRNA Vaccines
Yang Wang, Huaicheng Tan, Ting Yu, Xiaoxuan Chen, Fangqi Jing, Huashan Shi
Frontiers in Immunology.2021;[Epub] CrossRef
TRIM29 in Cutaneous Squamous Cell Carcinoma
Che-Yuan Hsu, Teruki Yanagi, Hideyuki Ujiie
Frontiers in Medicine.2021;[Epub] CrossRef
Molecular therapy with derivatives of amino benzoic acid inhibits tumor growth and metastasis in murine models of bladder cancer through inhibition of TNFα/NFΚB and iNOS/NO pathways
Julie Girouard, Denise Belgorosky, Jovane Hamelin-Morrissette, Valerie Boulanger, Ernesto D'Orio, Djamel Ramla, Robert Perron, Lucie Charpentier, Céline Van Themsche, Ana Maria Eiján, Gervais Bérubé, Carlos Reyes-Moreno
Biochemical Pharmacology.2020; 176: 113778. CrossRef
Loss of TRIM29 suppresses cancer stem cell-like characteristics of PDACs via accelerating ISG15 degradation
Jia Sun, Jing Yan, Huai-Yu Qiao, Fu-Ying Zhao, Chao Li, Jing-Yi Jiang, Bao-Qin Liu, Xiao-Na Meng, Hua-Qin Wang
Oncogene.2020; 39(3): 546. CrossRef
The Tripartite Nexus: Autophagy, Cancer, and Tripartite Motif-Containing Protein Family Members
Michael A. Mandell, Bhaskar Saha, Todd A. Thompson
Frontiers in Pharmacology.2020;[Epub] CrossRef
Macrophage Membrane-Coated Nanoparticles Alleviate Hepatic Ischemia-Reperfusion Injury Caused by Orthotopic Liver Transplantation by Neutralizing Endotoxin

Zhibing Ou, Hua Zhong, Liang Zhang, Minghua Deng, Wenfeng Zhang, Jingyuan Wang, Huaguo Feng, Jianping Gong, Chunmu Miao, Zhujun Yi
International Journal of Nanomedicine.2020; Volume 15: 4125. CrossRef
TRIM59 inhibits PPM1A through ubiquitination and activates TGF-β/Smad signaling to promote the invasion of ectopic endometrial stromal cells in endometriosis
Fengyu Wang, Haili Wang, Lei Sun, Chengling Niu, Jie Xu
American Journal of Physiology-Cell Physiology.2020; 319(2): C392. CrossRef
TRIM29 mediates lung squamous cell carcinoma cell metastasis by regulating autophagic degradation of E-cadherin
Weifeng Xu, Beibei Chen, Dianshan Ke, Xiaobing Chen
Aging.2020; 12(13): 13488. CrossRef
Long non‑coding RNA TP73‑AS1 accelerates the progression and cisplatin resistance of non‑small cell lung cancer by upregulating the expression of TRIM29 via competitively targeting microRNA‑34a‑5p
Shunxiang Luo, Ming Shen, Hui Chen, Weiwei Li, Cong Chen
Molecular Medicine Reports.2020;[Epub] CrossRef
Robust Sample-Specific Stability Selection with Effective Error Control
Heewon Park, Makoto Yamada, Seiya Imoto, Satoru Miyano
Journal of Computational Biology.2019; 26(3): 202. CrossRef
Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway
Hao Shen, Jiawei Zhang, Yaodong Zhang, Qinchao Feng, Hongwei Wang, Gaochao Li, Wangjie Jiang, Xiangcheng Li
Gene.2019; 698: 50. CrossRef
MicroRNA-424-5p acts as a potential biomarker and inhibits proliferation and invasion in hepatocellular carcinoma by targeting TRIM29
Huimin Du, Qing Xu, Sheng Xiao, Zhenru Wu, Jianping Gong, Changan Liu, Guosheng Ren, Hao Wu
Life Sciences.2019; 224: 1. CrossRef
ATDC contributes to sustaining the growth and invasion of glioma cells through regulating Wnt/β-catenin signaling
Yidong Cao, Luoning Shi, Maode Wang, Juanru Hou, Yanqiang Wei, Changwang Du
Chemico-Biological Interactions.2019; 305: 148. CrossRef
MicroRNA-621 inhibits cell proliferation and metastasis in bladder cancer by suppressing Wnt/β-catenin signaling
Haili Tian, Xiaoqiang Wang, Jianfeng Lu, Weiping Tian, Peijie Chen
Chemico-Biological Interactions.2019; 308: 244. CrossRef
Regulator of G protein signaling 20 promotes proliferation and migration in bladder cancer via NF-κB signaling
Gang Li, Meng Wang, Liangliang Ren, Hanzong Li, Qinghua Liu, Ying Ouyang, Lixin He, Fengyan Li
Biomedicine & Pharmacotherapy.2019; 117: 109112. CrossRef
ATDC promotes the growth and invasion of hepatocellular carcinoma cells by modulating GSK‐3β/Wnt/β‐catenin signalling
Weizhi Li, Hui Xue, Yingchao Li, Peijie Li, Fuquan Ma, Mengying Liu, Shuzhen Kong
Clinical and Experimental Pharmacology and Physiology.2019; 46(9): 845. CrossRef
MicroRNA-449a functions as a tumor suppressor in pancreatic cancer by the epigenetic regulation of ATDC expression
Feng Li, Jing Liang, Lu Bai
Biomedicine & Pharmacotherapy.2018; 103: 782. CrossRef
iTRAQ-based quantitative proteomic analysis of differentially expressed proteins in chemoresistant nasopharyngeal carcinoma
Kun Wang, Zhen Chen, Lu Long, Ya Tao, Qiong Wu, Manlin Xiang, Yunlai Liang, Xulin Xie, Yuan Jiang, Zhiqiang Xiao, Yahui Yan, Shiyang Qiu, Bin Yi
Cancer Biology & Therapy.2018; 19(9): 809. CrossRef
TRIM29 as a prognostic predictor for multiple human malignant neoplasms: a systematic review and meta-analysis
Chao Liang, Huiyu Dong, Chenkui Miao, Jundong Zhu, Jie Wang, Pu Li, Jie Li, Zengjun Wang
Oncotarget.2018; 9(15): 12323. CrossRef
Overexpression of sigma‑1 receptor in MCF‑7 cells enhances proliferation via the classic protein kinase C subtype signaling pathway
Yuqi Wu, Xueyan Bai, Xiaoyang Li, Chang Zhu, Zachary Wu
Oncology Letters.2018;[Epub] CrossRef
TRIM59 facilitates the proliferation of colorectal cancer and promotes metastasis via the PI3K/AKT pathway
Ye Sun, Bing Ji, Yifei Feng, Yue Zhang, Dongjian Ji, Chunyan Zhu, Sen Wang, Chuan Zhang, Dongsheng Zhang, Yueming Sun
Oncology Reports.2017; 38(1): 43. CrossRef
TRIM29 promotes progression of thyroid carcinoma via activating P13K/AKT signaling pathway
Jinkai Xu, Zongyu Li, Qinghua Su, Jun Zhao, Jiancang Ma
Oncology Reports.2017; 37(3): 1555. CrossRef
Intravesicular administration of sodium hyaluronate ameliorates the inflammation and cell proliferation of cystitis cystica et glandularis involving interleukin-6/JAK2/Stat3 signaling pathway
Yongliang Ni, Shaohua Zhao, Xiaoxuan Yin, Haixin Wang, Qianqian Guang, Guangxia Hu, Yi Yang, Shoubin Jiao, Benkang Shi
Scientific Reports.2017;[Epub] CrossRef
High expression of TRIM29 (ATDC) contributes to poor prognosis and tumor metastasis by inducing epithelial-mesenchymal transition in osteosarcoma
Si-Xiang Zeng, Qing-Chun Cai, Chi-Hua Guo, Li-Qiang Zhi, Xing Dai, Dang-Feng Zhang, Wei Ma
Oncology Reports.2017; 38(3): 1645. CrossRef
MicroRNA-186 regulates the invasion and metastasis of bladder cancer via vascular endothelial growth factor C
Xuefeng He, Jigen Ping, Duangai Wen
Experimental and Therapeutic Medicine.2017; 14(4): 3253. CrossRef

12,048 View
201 Download
43 Web of Science
40 Crossref

Is There a Role for Adjuvant Therapy in R0 Resected Gallbladder Cancer?: A Propensity Score-Matched Analysis: Se-Il Go, Young Saing Kim, In Gyu Hwang, Eun Young Kim, Sung Yong Oh, Jun Ho Ji, Haa-Na Song, Se Hoon Park, Joon Oh Park, Jung Hun Kang; Cancer Res Treat. 2016;48(4):1274-1285. Published online February 12, 2016; DOI: https://doi.org/10.4143/crt.2015.502

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to assess the role of adjuvant therapy in stage I-III gallbladder cancer (GBC) patients who have undergone R0 resection.
Materials and Methods
Clinical data were collected on 441 consecutive patients who underwent R0 resection for stage I-III GBC. Eligible patients were classified into adjuvant therapy and surveillance only groups. Propensity score matching (PSM) between the two groups was performed, adjusting clinical factors.
Results
In total, 84 and 279 patients treated with adjuvant therapy and followed up with surveillance only, respectively, were included in the analysis. Before PSM, the 5-year relapse-free survival (RFS) rate was lower in the adjuvant therapy group than in the surveillance only group (50.8% vs. 74.8%, p < 0.001), although there was no statistically significant difference in the 5-year overall survival (OS) rate (66.2% vs. 79.5%, p=0.089). After the PSM, baseline characteristics became comparable and there were no differences in the 5-year RFS (50.8% vs. 64.8%, p=0.319) and OS (66.2% vs. 70.4%, p=0.703) rates between the two groups.
Conclusion
The results suggest that fluoropyrimidine-based adjuvant therapy is not indicated in stage I-III GBC patients who have undergone R0 resection.

Citations

Citations to this article as recorded by

Prospective Randomized Controlled Trial Comparing Adjuvant Chemotherapy vs. No Chemotherapy for Patients with Carcinoma of Gallbladder Undergoing Curative Resection
Sundeep Singh Saluja, Phani Kumar Nekarakanti, Pramod Kumar Mishra, Anurita Srivastava, Kishore Singh
Journal of Gastrointestinal Surgery.2022; 26(2): 398. CrossRef
Adjuvant Therapy for Resectable Biliary Tract Cancer: A Bayesian Network Analysis
Xiuqiong Chen, Fanqiao Meng, Hua Xiong, Yanmei Zou
Frontiers in Oncology.2021;[Epub] CrossRef
Current standards and future perspectives in adjuvant treatment for biliary tract cancers
Angela Lamarca, Julien Edeline, Mairéad G McNamara, Richard A Hubner, Masato Nagino, John Bridgewater, John Primrose, Juan W Valle
Cancer Treatment Reviews.2020; 84: 101936. CrossRef
Prognostic factors and patterns of loco-regional failure in patients with R0 resected gallbladder cancer
Jung Ho Im, Woo Jung Lee, Chang Moo Kang, Ho Kyoung Hwang, Jinsil Seong
HPB.2020; 22(8): 1168. CrossRef
Prognostic Factors for Operated Gallbladder Cancer
Bala Basak Oven Ustaalioglu, Ahmet Bilici, Mesut Seker, Umut Kefeli, Dincer Aydin, Serkan Celik, Tarik Demir, Burcak Erkol
Journal of Gastrointestinal Cancer.2019; 50(3): 451. CrossRef
Role of Adjuvant Chemotherapy in Resected T2N0 Gall Bladder Cancer
Abhay K. Kattepur, Shraddha Patkar, Mahesh Goel, Anant Ramaswamy, Vikas Ostwal
Journal of Gastrointestinal Surgery.2019; 23(11): 2232. CrossRef
A systematic review of the effectiveness of adjuvant therapy for patients with gallbladder cancer
Carlos Manterola, Galo Duque, Luis Grande, Xabier de Aretxabala, Roque Conejeros, Tamara Otzen, Nayely García
HPB.2019; 21(11): 1427. CrossRef
Adjuvant Chemoradiotherapy is Associated with Improved Survival for Patients with Resected Gallbladder Carcinoma: A Systematic Review and Meta-analysis
Byoung Hyuck Kim, Jeanny Kwon, Eui Kyu Chie, Kyubo Kim, Young Hoon Kim, Dong Wan Seo, Amol K. Narang, Joseph M. Herman
Annals of Surgical Oncology.2018; 25(1): 255. CrossRef
Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer
T Ebata, S Hirano, M Konishi, K Uesaka, Y Tsuchiya, M Ohtsuka, Y Kaneoka, M Yamamoto, Y Ambo, Y Shimizu, F Ozawa, A Fukutomi, M Ando, Y Nimura, M Nagino, S Nakamori, T Ajiki, H Baba, R Yamaguchi, M Kawai, H Nagano, F Miura, T Arai, Y Nishiwaki, S Kawasaki
British Journal of Surgery.2018; 105(3): 192. CrossRef
Adjuvant systemic therapy and postoperative outcomes after resection of node positive gallbladder cancer
Jiong-Jie Yu, Xin-Fei Xu, Tian Yang
International Journal of Surgery.2018; 54: 307. CrossRef
The efficiency and regimen choice of adjuvant chemotherapy in biliary tract cancer
Luxi Yin, Qi Xu, Jingjing Li, Qing Wei, Jieer Ying
Medicine.2018; 97(50): e13570. CrossRef
Surgical Management of Gallbladder Cancer
Gyulnara G. Kasumova, Omidreza Tabatabaie, Robert M. Najarian, Mark P. Callery, Sing Chau Ng, Andrea J. Bullock, Robert A. Fisher, Jennifer F. Tseng
Annals of Surgery.2017; 266(4): 625. CrossRef

14,967 View
203 Download
17 Web of Science
12 Crossref

Decision Based on Narrow Band Imaging Cystoscopy without a Referential Normal Standard Rather Increases Unnecessary Biopsy in Detection of Recurrent Bladder Urothelial Carcinoma Early after Intravesical Instillation: Phil Hyun Song, Seok Cho, Young Hwii Ko; Cancer Res Treat. 2016;48(1):273-280. Published online March 2, 2015; DOI: https://doi.org/10.4143/crt.2014.190

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to calculate the operating characteristics of narrowband imaging (NBI) cystoscopy versus traditional white light cystoscopy (WLC) in common clinical scenarios involving suspicion of bladder urothelial carcinoma (UC). Materials and Methods Sixty-three consecutive patients initially underwent WLC and then NBI in a single session for evaluation of microscopic hematuria (group I, n=20), gross hematuria (group II, n=19), and follow-up for prior UC (group III, n=24), by an experienced urologist. All lesions that were abnormal in contrast with adjacent normal mucosa were diagnosed as positive and biopsied.
Results
Sixty-six biopsies from 47 patients were performed. Pathologic examination showed 17 cases of UC from 21 sites. While the overall sensitivity of NBI was similar to that of WLC (100% vs. 94.1%), the specificity of NBI was significantly lower than that of WLC (50% vs. 86.9%, p < 0.001), particularly in group III (38.9% vs. 88.9%, p=0.004). Based on identification by NBI only, 23 additional biopsies from 18 cases were performed for identification of one patient with UC, who belonged to group III. In this group, to identify this specific patient, 15 additional biopsies were performed from 10 patients. All seven cases with positive findings from NBI within 2 months after the last intravesical therapy were histologically proven as negative. Conclusion In evaluation for recurrence early after intravesical instillation, the decision based on NBI increased unnecessary biopsy in the absence of an established standard for judging NBI.

Citations

Citations to this article as recorded by

Comparison of narrow band imaging versus white light imaging in detecting non muscle invasive bladder cancer
Raghavendra RT, Amit Sharma, Deepak Biswal, Saryu Goel
Urologia Journal.2024; 91(2): 289. CrossRef
Advanced optical imaging techniques for bladder cancer detection and diagnosis: a systematic review
Marinka J. Remmelink, Yael Rip, Jakko A. Nieuwenhuijzen, Johannes C.F. Ket, Jorg R. Oddens, Theo M. de Reijke, Daniel M. de Bruin
BJU International.2024; 134(6): 890. CrossRef
Differentiation of Urothelial Carcinoma and Normal Bladder Tissues by Means of Fiber-Based ATR IR Spectroscopy
Rimantė Bandzevičiūtė, Gediminas Platkevičius, Justinas Čeponkus, Arūnas Želvys, Albertas Čekauskas, Valdas Šablinskas
Cancers.2023; 15(2): 499. CrossRef
Development and validation of a predictive model for the diagnosis of bladder tumors using narrow band imaging
Hao Liang, Qingya Yang, Yaozhong Zhang, Hui Sun, Qiang Fu, Tongxiang Diao, Jin Wang, Wei Huang, Yang Xu, Nan Ge, Xuewen Jiang, Shouzhen Chen, Yan Li, Bin Zhou, Peixin Li, Xiaoyi Zhang, Nianzhao Zhang, Benkang Shi, Jun Chen
Journal of Cancer Research and Clinical Oncology.2023; 149(17): 15867. CrossRef
Role of Macroscopic Image Enhancement in Diagnosis of Non-Muscle-Invasive Bladder Cancer: An Analytical Review
Prashant Motiram Mulawkar, Gyanendra Sharma, Ashwin Tamhankar, Utsav Shah, Rickaz Raheem
Frontiers in Surgery.2022;[Epub] CrossRef
Performance of Narrow Band Imaging (NBI) and Photodynamic Diagnosis (PDD) Fluorescence Imaging Compared to White Light Cystoscopy (WLC) in Detecting Non-Muscle Invasive Bladder Cancer: A Systematic Review and Lesion-Level Diagnostic Meta-Analysis
Giorgio I. Russo, Tamir N. Sholklapper, Andrea Cocci, Giuseppe Broggi, Rosario Caltabiano, Angela B. Smith, Yair Lotan, Giuseppe Morgia, Ashish M. Kamat, J. Alfred Witjes, Siamak Daneshmand, Mihir M. Desai, Indebir S. Gill, Giovanni E. Cacciamani
Cancers.2021; 13(17): 4378. CrossRef
Postoperative Recurrent Bladder Tumors Detection by Narrow-Band Imaging Cystoscopy
Won Tae Seo, Su Hwan Kang
The Korean Journal of Urological Oncology.2020; 18(3): 209. CrossRef
Blue-light cystoscopy and narrow-band imaging in bladder cancer management
Zhijiang Zang, Qinghui Wu, Edmund Chiong
Formosan Journal of Surgery.2019; 52(5): 155. CrossRef
Usefulness of narrow-band imaging in transurethral resection of bladder tumor: Early experience from a tertiary center in India
Kanuj Malik, Anand Raja, Sivakumar Mahalingam, L.S Ravishankar
South Asian Journal of Cancer.2019; 08(04): 226. CrossRef
Diagnostic performance of image technique based transurethral resection for non-muscle invasive bladder cancer: systematic review and diagnostic meta-analysis
Changhao Chen, Hao Huang, Yue Zhao, Hao Liu, Richard Sylvester, Tianxin Lin, Jian Huang
BMJ Open.2019; 9(10): e028173. CrossRef
Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: Prospective, randomized comparison with white light cystoscopy
Seung Bin Kim, Sung Goo Yoon, Jonghyun Tae, Jae Yoon Kim, Ji Sung Shim, Sung Gu Kang, Jun Cheon, Jeong Gu Lee, Je Jong Kim, Seok Ho Kang
Investigative and Clinical Urology.2018; 59(2): 98. CrossRef
A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer
YiQuan Xiong, JianDong Li, ShuJuan Ma, Jing Ge, LiZhi Zhou, Dongliang Li, Qing Chen, Robert Hurst
PLOS ONE.2017; 12(2): e0170819. CrossRef
Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: A systematic review and meta-analysis
Weiting Kang, Zilian Cui, Qianqian Chen, Dong Zhang, Haiyang Zhang, Xunbo Jin
Oncotarget.2017; 8(14): 23880. CrossRef
Narrow band imaging for bladder cancer
Thomas Y. Hsueh, Allen W. Chiu
Asian Journal of Urology.2016; 3(3): 126. CrossRef

13,303 View
86 Download
14 Web of Science
14 Crossref

Detecting Metastatic Bladder Cancer Using ¹⁸F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography: Hakan Öztürk; Cancer Res Treat. 2015;47(4):834-843. Published online February 12, 2015; DOI: https://doi.org/10.4143/crt.2014.157

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to retrospectively investigate the contribution of 18F-fluorodeoxyglucose- positron emission tomography/computed tomography (18F-FDG-PET/CT) to detection of metastatic bladder cancer. Materials and Methods The present study included 79 patients (69 men and 10 women) undergoing 18F-FDGPET/ CT upon suspicion of metastatic bladder cancer between July 2007 and April 2013. The mean age was 66.1 years with a standard deviation of 10.7 years (range, 21 to 85 years). Patients were required to fast for 6 hours prior to scanning, and whole-body PET scanning from the skull base to the upper thighs was performed approximately 1 hour after intravenous injection of 555 MBq of 18F-FDG. Whole body CT scanning was performed in the cranio-caudal direction. FDG-PET images were reconstructed using CT data for attenuation correction. Suspicious recurrent or metastatic lesions were confirmed by histopathology or clinical follow-up. Results The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 18F-FDG-PET/CT were 89%, 78%, 90%, 75%, and 86%, respectively. Conclusion 18F-FDG-PET/CT can detect metastases with high sensitivity and positive predictive values in patients with metastatic bladder carcinoma.

Citations

Citations to this article as recorded by

Radiotherapy in metastatic bladder cancer
Sophie Ashley, Ananya Choudhury, Peter Hoskin, YeePei Song, Priyamvada Maitre
World Journal of Urology.2024;[Epub] CrossRef
PET Imaging in Bladder Cancer: An Update and Future Direction
Jules Zhang-Yin, Antoine Girard, Etienne Marchal, Thierry Lebret, Marie Homo Seban, Marine Uhl, Marc Bertaux
Pharmaceuticals.2023; 16(4): 606. CrossRef
Accuracy of FDG-PET/CT for Response Evaluation of Muscle-Invasive Bladder Cancer following Neoadjuvant or Induction Chemotherapy
Olivier Fitoussi, Jean Baptiste Roche, Julien Riviere, Hervé Wallerand, Jean Eude Poulain, Pierre Gordien, Sigolène Galland, Bénédicte Henriques, Camille Dupin, Muriel Vincent, Thomas Kuratle, Mo Saffarini, Sonia Ramos-Pascual
Urologia Internationalis.2023; 107(3): 239. CrossRef
PET/CT in Bladder Cancer: An Update
Kirsten Bouchelouche
Seminars in Nuclear Medicine.2022; 52(4): 475. CrossRef
Quantitative positron emission tomography imaging in the presence of iodinated contrast media using electron density quantifications from dual‐energy computed tomography
Nadav Shapira, Joshua Scheuermann, Amy E. Perkins, Johoon Kim, Leening P Liu, Joel S. Karp, Peter B. Noël
Medical Physics.2021; 48(1): 273. CrossRef
18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in muscle-invasive bladder cancer
Sarah M.H. Einerhand, Erik J. van Gennep, Laura S. Mertens, Kees Hendricksen, Maarten L. Donswijk, Henk G. van der Poel, Bas W.G. van Rhijn
Current Opinion in Urology.2020; 30(5): 654. CrossRef
The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma
Antoine Girard, Helena Vila Reyes, Hiram Shaish, Jean-François Grellier, Laurent Dercle, Pierre-Yves Salaün, Olivier Delcroix, Mathieu Rouanne
Frontiers in Oncology.2020;[Epub] CrossRef
Cancers de la vessie
A. Girard, J.F. Grellier, P.Y. Salaün
Médecine Nucléaire.2019; 43(1): 69. CrossRef
Comment on: Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer
Antoine Girard, Mathieu Rouanne
European Journal of Nuclear Medicine and Molecular Imaging.2019; 46(6): 1212. CrossRef
Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study
Fabio Zattoni, Elena Incerti, Michele Colicchia, Paolo Castellucci, Stefano Panareo, Maria Picchio, Federico Fallanca, Alberto Briganti, Marco Moschini, Andrea Gallina, Jeffrey R. Karnes, Val Lowe, Stefano Fanti, Riccardo Schiavina, Ilaria Rambaldi, Vince
Abdominal Radiology.2018; 43(9): 2391. CrossRef
The role of PET/CT in the evaluation of patients with urothelial cancer: a systematic review and meta-analysis
Anna Rita Cervino, Lea Cuppari, Pasquale Reccia, Marta Burei, Giorgio Saladini, Laura Evangelista
Clinical and Translational Imaging.2018; 6(2): 77. CrossRef
Pelvic Lymph Node Staging by Combined 18 F-FDG-PET/CT Imaging in Bladder Cancer Prior to Radical Cystectomy
Renate Pichler, Tobias De Zordo, Josef Fritz, Alexander Kroiss, Friedrich Aigner, Isabel Heidegger, Irene Virgolini, Wolfgang Horninger, Christian Uprimny
Clinical Genitourinary Cancer.2017; 15(3): e387. CrossRef
Metabolic coupling in urothelial bladder cancer compartments and its correlation to tumor aggressiveness
Julieta Afonso, Lúcio L. Santos, António Morais, Teresina Amaro, Adhemar Longatto-Filho, Fátima Baltazar
Cell Cycle.2016; 15(3): 368. CrossRef
The importance of clinical stage among patients with a complete pathologic response at radical cystectomy after neoadjuvant chemotherapy
William P. Parker, Philip L. Ho, Stephen A. Boorjian, Jonathan J. Melquist, Prabin Thapa, Jeffrey M. Holzbeierlein, Igor Frank, Ashish M. Kamat, Eugene K. Lee
World Journal of Urology.2016; 34(11): 1561. CrossRef

15,310 View
100 Download
18 Web of Science
14 Crossref

APE1/Ref-1 as a Serological Biomarker for the Detection of Bladder Cancer: Ju Hyun Shin, Sunga Choi, Yu Ran Lee, Myoung Soo Park, Yong Gil Na, Kaikobad Irani, Sang Do Lee, Jin Bong Park, Jin Man Kim, Jae Sung Lim, Byeong Hwa Jeon; Cancer Res Treat. 2015;47(4):823-833. Published online January 2, 2015; DOI: https://doi.org/10.4143/crt.2014.074

Abstract PDF PubReader ePub

Purpose
Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) is a multifunctional protein that shows elevated expression in a number of cancers. We attempted to determine whether serum APE1/Ref-1 is elevated in patients with bladder cancer.
Materials and Methods
Serum APE1/Ref-1 levels were determined using enzyme-linked immunosorbent assay in serum from patients with bladder cancer who had not received chemotherapy or radiotherapy (n=51) and non-tumor controls (n=55). The area under the receiver operating characteristic area under the curve was applied to determine the correlation between clinical factors and the serum levels of APE1/Ref-1.
Results
Serum levels of APE1/Ref-1 in bladder cancer patients were significantly elevated compared to those of the control group (3.548±0.333 ng/100 μL [n=51] for bladder cancer vs. 1.547±0.319 ng/100 μL [n=55] for the control group), with a sensitivity and specificity of 93% and 59%, respectively. Serum APE1/Ref-1 levels are associated with tumor stage, grade, muscle invasion, and recurrence.
Conclusion
Serum APE1/Ref-1 might be useful as a potential serologic biomarker for bladder cancer.

Citations

Citations to this article as recorded by

Leveraging CRISPR/Cas12 signal amplifier to sensitive detection of apurinic/apyrimidinic endonuclease 1 and high-throughput inhibitor screening
Sheng Ding, Yi Yuan, Juan Dong, Feng Du, Xin Cui, Zheng Shi, Zhuo Tang
Analytica Chimica Acta.2024; 1291: 342212. CrossRef
Protective effect of secretory APE1/Ref‐1 on doxorubicin‐induced cardiotoxicity via suppression of ROS and p53 pathway
Soo Yeon An, Seon‐Ah Jin, Hee Jeong Seo, Yu Ran Lee, Sungmin Kim, Byeong Hwa Jeon, Jin‐Ok Jeong
ESC Heart Failure.2024; 11(2): 1182. CrossRef
Enhancing APE1 detection through apurinic/apyrimidinic site inhibition of DNA polymerase: an innovative, highly sensitive approach
Zhijun Liu, Bei Yan, Huan Liu, Xiao Liu, Xianjin Xiao, Zhihao Ming
Chemical Communications.2024; 60(35): 4695. CrossRef
The DNA-repair protein APE1 participates with hnRNPA2B1 to motif-enriched and prognostic miRNA secretion
Giovanna Mangiapane, Michela Notarangelo, Giulia Canarutto, Fabrizio Fabbiano, Emiliano Dalla, Monica Degrassi, Giulia Antoniali, Nicolò Gualandi, Veronica De Sanctis, Silvano Piazza, Vito Giuseppe D’Agostino, Gianluca Tell
Oncogene.2024; 43(24): 1861. CrossRef
Dual-driven AND molecular logic gates for label-free and sensitive ratiometric fluorescence sensing and inhibitors screening
Qiongdan Zhang, Qingyi Liu, Gang Fu, Feibing Huang, Yanfu Tang, Yixing Qiu, Anqi Ge, Jinhui Hu, Wei Wang, Bin Li, Huizhen Wang
Journal of Colloid and Interface Science.2024; 674: 841. CrossRef
A recognition-induced three-dimensional bipedal DNA walker for highly sensitive detection of APE1
Qingyi Liu, Qiongdan Zhang, Yuting Zhang, Fanghong Tian, Kang Long, Yupei Yang, Wei Wang, Caiyun Peng, Huizhen Wang
Analytical Methods.2024; 16(36): 6220. CrossRef
Role of APE1 in hepatocellular carcinoma and its prospects as a target in clinical settings (Review)
Lei Yang, Zhipeng Sun
Molecular and Clinical Oncology.2024;[Epub] CrossRef
A multifunctional DNA repair enzyme and magnetic dual-triggered theranostic nanosystem for intelligent drug delivery
Zhuo Peng, Keni Ning, Xiaoyan Tang, Ruikai He, Dong-Yang Zhang, Yan Ma, Shixia Guan, Junqiu Zhai
Materials & Design.2023; 226: 111611. CrossRef
Electrochemical biosensor based on bipedal DNA walker for highly sensitive amplification detection of apurinic/apyrimidinic endonuclease 1
Xingcong Wang, Jinting Meng, Haoping Zhang, Jingyan Mou, Jinping Xiong, Hong Wang, Xin Su, Yingwei Zhang
Sensors and Actuators B: Chemical.2023; 381: 133425. CrossRef
An AND‐Gate DNA Nanodevice for Dual Protein‐Mediated, Tumor‐Specific Imaging
Zetan Fan, Fangzhi Yu, Mingming Yu, Lele Li
Chinese Journal of Chemistry.2023; 41(12): 1437. CrossRef
Revisiting Two Decades of Research Focused on Targeting APE1 for Cancer Therapy: The Pros and Cons
Matilde Clarissa Malfatti, Alessia Bellina, Giulia Antoniali, Gianluca Tell
Cells.2023; 12(14): 1895. CrossRef
Elevated Plasma Apurinic/Apyrimidinic Endonuclease 1/Redox Effector Factor-1 Levels in Refractory Kawasaki Disease
Yu-Ran Lee, Eun Young Bae, Hong Ryang Kil, Byeong-Hwa Jeon, Geena Kim
Biomedicines.2022; 10(1): 190. CrossRef
Mechanistic decoupling of exonuclease III multifunctionality into AP endonuclease and exonuclease activities at the single-residue level
Donghun Lee, Sanghoon Oh, HyeokJin Cho, Jungmin Yoo, Gwangrog Lee
Nucleic Acids Research.2022; 50(4): 2211. CrossRef
APE1/Ref-1 Role in Inflammation and Immune Response
Thais Teixeira Oliveira, Leonam Gomes Coutinho, Laysa Ohana Alves de Oliveira, Ana Rafaela de Souza Timoteo, Guilherme Cavalcanti Farias, Lucymara Fassarella Agnez-Lima
Frontiers in Immunology.2022;[Epub] CrossRef
“RESET” Effect: Random Extending Sequences Enhance the Trans-Cleavage Activity of CRISPR/Cas12a
Jia-Yi Ma, Si-Yuan Wang, Yi-Chen Du, Dong-Xia Wang, An-Na Tang, Jing Wang, De-Ming Kong
Analytical Chemistry.2022; 94(22): 8050. CrossRef
A dual-functional fluorescent biosensor based on enzyme-involved catalytic hairpin assembly for the detection of APE1 and miRNA-21
Xiaoyong Lu, Dan Li, Zewei Luo, Yixiang Duan
The Analyst.2022; 147(12): 2834. CrossRef
Incorporating quaternary mesoporous nanospheres and DNA stochastic nanowalkers into a signal amplified switch: A highly sensitive electrochemical assay for APE1
Qingsong Wei, Zhisheng Teng, Xuelian Luo, Yuxin Yang, Yuxia Ren, Wenbin Liang, Ying Zhuo, Zhaoyang Zhong
Sensors and Actuators B: Chemical.2022; 370: 132386. CrossRef
Identification and Quantification of Apurinic/Apyrimidinic Endonuclease 1 in Human Peripheral Blood Leukocytes by Liquid Chromatography/Isotope-Dilution High Resolution Mass Spectrometry
Gamze TUNA
Journal of Basic and Clinical Health Sciences.2022; 6(3): 851. CrossRef
The multifunctional APE1 DNA repair–redox signaling protein as a drug target in human disease
Rachel A. Caston, Silpa Gampala, Lee Armstrong, Richard A. Messmann, Melissa L. Fishel, Mark R. Kelley
Drug Discovery Today.2021; 26(1): 218. CrossRef
A DNA structure-mediated fluorescent biosensor for apurinic/apyrimidinic endonuclease 1 activity detection with ultra-high sensitivity and selectivity
Yuqiang Hu, Zhen Zhang, Weicong Ye, Wei Zhang, Minghao Hu, Wenqian Yuan, Hongbo Wang, Xianjin Xiao, Tongbo Wu
Sensors and Actuators B: Chemical.2021; 330: 129332. CrossRef
Spectroscopic sensing and quantification of AP-endonucleases using fluorescence-enhancement by cis–trans isomerization of cyanine dyes
JunHo Cho, Sanghoon Oh, DongHun Lee, Jae Won Han, Jungmin Yoo, Daeho Park, Gwangrog Lee
RSC Advances.2021; 11(19): 11380. CrossRef
Enzymatically active apurinic/apyrimidinic endodeoxyribonuclease 1 is released by mammalian cells through exosomes
Giovanna Mangiapane, Isabella Parolini, Kristel Conte, Matilde Clarissa Malfatti, Jessica Corsi, Massimo Sanchez, Agostina Pietrantoni, Vito G. D’Agostino, Gianluca Tell
Journal of Biological Chemistry.2021; 296: 100569. CrossRef
APE1 and SSRP1 is overexpressed in muscle invasive bladder cancer and associated with poor survival
Heyu Song, Jiping Zeng, Subodh Lele, Chad A. LaGrange, Kishor K. Bhakat
Heliyon.2021; 7(4): e06756. CrossRef
Cephalomannine inhibits hypoxia-induced cellular function via the suppression of APEX1/HIF-1α interaction in lung cancer
Asmat Ullah, Sze Wei Leong, Jingjing Wang, Qing Wu, Mohsin Ahmad Ghauri, Ammar Sarwar, Qi Su, Yanmin Zhang
Cell Death & Disease.2021;[Epub] CrossRef
A Cooperatively Activatable, DNA‐based Fluorescent Reporter for Imaging of Correlated Enzymatic Activities
Zetan Fan, Jian Zhao, Xin Chai, Lele Li
Angewandte Chemie.2021; 133(27): 15013. CrossRef
A Cooperatively Activatable, DNA‐based Fluorescent Reporter for Imaging of Correlated Enzymatic Activities
Zetan Fan, Jian Zhao, Xin Chai, Lele Li
Angewandte Chemie International Edition.2021; 60(27): 14887. CrossRef
Blood-based protein biomarkers in bladder urothelial tumors
Rubén López-Cortés, Benito Blanco Gómez, Sergio Vázquez-Estévez, Daniel Pérez-Fentes, Cristina Núñez
Journal of Proteomics.2021; 247: 104329. CrossRef
Changes in the Plasma Apurinic/Apyrimidinic Endonuclease 1/Redox Factor-1(APE1/Ref-1) Level during Cancer Surgery: An Observational Study
Yumin Jo, Yeojung Kim, Eunhye Park, Yuran Lee, Jiyeon Kim, Minwoong Kang, Jaesung Lim, Insang Song, Chaeseong Lim, Byeonghwa Jeon
Medicina.2021; 57(11): 1280. CrossRef
Nucleases as molecular targets for cancer diagnosis
Alien Balian, Frank J. Hernandez
Biomarker Research.2021;[Epub] CrossRef
Graphene Quantum Dot-Based Nanocomposites for Diagnosing Cancer Biomarker APE1 in Living Cells
Hao Zhang, Sai Ba, Zhaoqi Yang, Tianxiang Wang, Jasmine Yiqin Lee, Tianhu Li, Fangwei Shao
ACS Applied Materials & Interfaces.2020; 12(12): 13634. CrossRef
The Biological Role of Apurinic/Apyrimidinic Endonuclease1/Redox Factor-1 as a Therapeutic Target for Vascular Inflammation and as a Serologic Biomarker
Yu Ran Lee, Hee Kyoung Joo, Byeong Hwa Jeon
Biomedicines.2020; 8(3): 57. CrossRef
Non-muscle invasive bladder cancer tissues have increased base excision repair capacity
Berna Somuncu, Selcuk Keskin, Fatma Merve Antmen, Yesim Saglican, Aysegul Ekmekcioglu, Tugce Ertuzun, Mustafa Bilal Tuna, Can Obek, David M. Wilson, Umit Ince, Ali Riza Kural, Meltem Muftuoglu
Scientific Reports.2020;[Epub] CrossRef
Correlation of APE1 with VEGFA and CD163+ macrophage infiltration in bladder cancer and their prognostic significance
Lin-Ang Wang, Bo Yang, Tang Tang, Yuxin Yang, Dianzheng Zhang, Hualiang Xiao, Jing Xu, Luofu Wang, Li Lin, Jun Jiang
Oncology Letters.2020; 20(3): 2881. CrossRef
Apurinic/Apyrimidinic Endonuclease 1/Redox Factor-1 Could Serve as a Potential Serological Biomarker for the Diagnosis and Prognosis of Oral Squamous Cell Carcinoma
Jianli Xie, Ying Li, Jingjing Kong, Chong Li
Journal of Oral and Maxillofacial Surgery.2019; 77(4): 859. CrossRef
The extracellular role of Ref-1 as anti-inflammatory function in lipopolysaccharide-induced septic mice
Hee Kyoung Joo, Yu Ran Lee, Eun-Ok Lee, Myoung Soo Park, Sunga Choi, Cuk-Seong Kim, Jin-Bong Park, Byeong Hwa Jeon
Free Radical Biology and Medicine.2019; 139: 16. CrossRef
ATP Binding Cassette Transporter A1 is Involved in Extracellular Secretion of Acetylated APE1/Ref-1
Yu Ran Lee, Hee Kyoung Joo, Eun Ok Lee, Hyun Sil Cho, Sunga Choi, Cuk-Seong Kim, Byeong Hwa Jeon
International Journal of Molecular Sciences.2019; 20(13): 3178. CrossRef
An electrochemical biosensor integrating immunoassay and enzyme activity analysis for accurate detection of active human apurinic/apyrimidinic endonuclease 1
Mengru Zhou, Chang Feng, Dongsheng Mao, Shiqi Yang, Lingjie Ren, Guifang Chen, Xiaoli Zhu
Biosensors and Bioelectronics.2019; 142: 111558. CrossRef
APEX1 Expression as a Potential Diagnostic Biomarker of Clear Cell Renal Cell Carcinoma and Hepatobiliary Carcinomas
Ji-Myung Kim, Min-Kyung Yeo, Jae Lim, In-Sang Song, Kwangsik Chun, Kyung-Hee Kim
Journal of Clinical Medicine.2019; 8(8): 1151. CrossRef
Serum Apurinic/Apyrimidinic Endodeoxyribonuclease 1 (APEX1) Level as a Potential Biomarker of Cholangiocarcinoma
Doungdean Tummanatsakun, Tanakorn Proungvitaya, Sittiruk Roytrakul, Temduang Limpaiboon, Sopit Wongkham, Chaisiri Wongkham, Atit Silsirivanit, Ongart Somintara, Sakkarn Sangkhamanon, Siriporn Proungvitaya
Biomolecules.2019; 9(9): 413. CrossRef
Serum AP-endonuclease 1 (sAPE1) as novel biomarker for hepatocellular carcinoma
Devis Pascut, Caecilia Hapsari Ceriapuri Sukowati, Giulia Antoniali, Giovanna Mangiapane, Silvia Burra, Luca Giovanni Mascaretti, Matteo Rossano Buonocore, Lory Saveria Crocè, Claudio Tiribelli, Gianluca Tell
Oncotarget.2019; 10(3): 383. CrossRef
Apurinic/apyrimidinic endonuclease/redox factor 1 (APE1) alleviates myocardial hypoxia‑reoxygenation injury by inhibiting oxidative stress and ameliorating mitochondrial dysfunction
Jie Hao, Hong Du, Fan Liu, Jing‑Chao Lu, Xiu‑Chun Yang, Wei Cui
Experimental and Therapeutic Medicine.2019;[Epub] CrossRef
Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer
Melissa L. Fishel, Hanyu Xia, Jack McGeown, David W. McIlwain, May Elbanna, Ariel A. Craft, Hristos Z. Kaimakliotis, George E. Sandusky, Chi Zhang, Roberto Pili, Mark R. Kelley, Travis J. Jerde
Molecular Cancer Therapeutics.2019; 18(11): 1947. CrossRef
Therapeutic positioning of secretory acetylated APE1/Ref-1 requirement for suppression of tumor growth in triple-negative breast cancer in vivo
Yu Ran Lee, Myoung Soo Park, Hee Kyoung Joo, Ki Mo Kim, Jeryong Kim, Byeong Hwa Jeon, Sunga Choi
Scientific Reports.2018;[Epub] CrossRef
Differential expression of APE1 in hepatocellular carcinoma and the effects on proliferation and apoptosis of cancer cells
Zhipeng Sun, Yubing Zhu, Aminbuhe, Qing Fan, Jirun Peng, Nengwei Zhang
BioScience Trends.2018; 12(5): 456. CrossRef
DNA base excision repair proteins APE‐1 and XRCC‐1 are overexpressed in oral tongue squamous cell carcinoma
Thalita Santana, Melka Coêlho Sá, Edilmar de Moura Santos, Hébel Cavalcanti Galvão, Ricardo D. Coletta, Roseana de Almeida Freitas
Journal of Oral Pathology & Medicine.2017; 46(7): 496. CrossRef
A graphene oxide-based tool-kit capable of characterizing and classifying exonuclease activities
Jayeon Song, Vo Minh Hoa, Jungmin Yoo, Sanghoon Oh, Hyeryeon Im, Daeho Park, Gwangrog Lee
RSC Advances.2017; 7(24): 14917. CrossRef
Apurinic/apyrimidinic endonuclease 1 (APE1) is overexpressed in malignant transformation of salivary gland pleomorphic adenoma
Leorik Pereira Silva, Thalita Santana, Bruno Tavares Sedassari, Suzana Machado de Sousa, Ana Paula Veras Sobral, Roseana de Almeida Freitas, Carlos Augusto Galvão Barboza, Lélia Batista de Souza
European Archives of Oto-Rhino-Laryngology.2017; 274(8): 3203. CrossRef
Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic
Fenil Shah, Derek Logsdon, Richard A. Messmann, Jill C. Fehrenbacher, Melissa L. Fishel, Mark R. Kelley
npj Precision Oncology.2017;[Epub] CrossRef
APE1/Ref‐1 knockdown in pancreatic ductal adenocarcinoma – characterizing gene expression changes and identifying novel pathways using single‐cellRNAsequencing
Fenil Shah, Emery Goossens, Nadia M. Atallah, Michelle Grimard, Mark R. Kelley, Melissa L. Fishel
Molecular Oncology.2017; 11(12): 1711. CrossRef
Elevation of Serum APE1/Ref-1 in Experimental Murine Myocarditis
Seon-Ah Jin, Byung-Kwan Lim, Hee Seo, Sun Kim, Kye Ahn, Byeong Jeon, Jin-Ok Jeong
International Journal of Molecular Sciences.2017; 18(12): 2664. CrossRef
APE1 overexpression is associated with poor survival in patients with solid tumors: a meta-analysis
Chun-Ling Yuan, Fan He, Jia-Zhou Ye, Hui-Ni Wu, Jin-Yan Zhang, Zhi-Hui Liu, Yong-Qiang Li, Xiao-Ling Luo, Yan Lin, Rong Liang
Oncotarget.2017; 8(35): 59720. CrossRef
Urinary APE1/Ref-1: A Potential Bladder Cancer Biomarker
Sunga Choi, Ju Hyun Shin, Yu Ran Lee, Hee Kyoung Joo, Ki Hak Song, Yong Gil Na, Seok Jong Chang, Jae Sung Lim, Byeong Hwa Jeon
Disease Markers.2016; 2016: 1. CrossRef
Secreted APE1/Ref-1 inhibits TNF-α-stimulated endothelial inflammation via thiol-disulfide exchange in TNF receptor
Myoung Soo Park, Sunga Choi, Yu Ran Lee, Hee Kyoung Joo, Gun Kang, Cuk-Seong Kim, Soo Jin Kim, Sang Do Lee, Byeong Hwa Jeon
Scientific Reports.2016;[Epub] CrossRef
Altered Secretory Activity of APE1/Ref-1 D148E Variants Identified in Human Patients With Bladder Cancer
Yu Ran Lee, Jae Sung Lim, Ju Hyun Shin, Sunga Choi, Hee Kyoung Joo, Byeong Hwa Jeon
International Neurourology Journal.2016; 20(Suppl 1): S30. CrossRef
Dynamic Regulation of APE1/Ref-1 as a Therapeutic Target Protein
Sunga Choi, Hee Kyoung Joo, Byeong Hwa Jeon
Chonnam Medical Journal.2016; 52(2): 75. CrossRef
Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients
Shiheng Zhang, Le He, Nan Dai, Wei Guan, Jinlu Shan, Xueqin Yang, Zhaoyang Zhong, Yi Qing, Feng Jin, Chuan Chen, Yuxin Yang, Hongyi Wang, Laura Baugh, Gianluca Tell, David M. Wilson, Mengxia Li, Dong Wang
Oncotarget.2016; 7(47): 77482. CrossRef

14,928 View
135 Download
57 Web of Science
56 Crossref

Case Report

A Case of Synchronous Double Primary Cancer of the Penis and Urinary Bladder: Yong Soo Cho, Jung-Ae Lee, Si Bum Kim, Soo Jung Gong, Joo Heon Kim, Seon Min Youn, Eun Tak Kim; Cancer Res Treat. 2010;42(1):53-56. Published online March 31, 2010; DOI: https://doi.org/10.4143/crt.2010.42.1.53

Abstract PDF PubReader ePub

Multiple primary cancers are the occurrence of more than two cancers of different origin in an individual. Penile cancer is a rare disease, and finding it combined with other cancers is even rarer. A 64-year-old man with a painful penile mass was referred to us from a primary urological clinic. We performed a biopsy of the penile mass and the histology revealed a well-differentiated squamous cell carcinoma. Abdominal computed tomography showed a localized bladder tumor with inguinal lymphadenopathy. The patient underwent a partial penectomy, transurethral resection of the bladder tumor and inguinal lymph node dissection. The histology of the bladder tumor was high-grade papillary carcinoma, and that of the lymph node was squamous cell carcinoma. The penile and bladder tumors were in stage II (T1N1M0) and stage I (T1N0M0), respectively. We successfully treated the patient with adjuvant radiotherapy and systemic chemotherapy.

Citations

Citations to this article as recorded by

Synchronous Double Primary Cancer of the Penisand Urinary Bladder
Deora H
MOJ Surgery.2017;[Epub] CrossRef

8,792 View
93 Download
1 Crossref

Original Articles

Co-Expression of Cox-2, C-Met and β-catenin in Cells Forming Invasive front of Gallbladder Cancer: Woo Sung Moon, Ho Sung Park, Ho Lee, Rama Pai, Andrzej S. Tarnawski, Kyung Ryoul Kim, Kyu Yun Jang; Cancer Res Treat. 2005;37(3):171-176. Published online June 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.3.171

Abstract PDF PubReader ePub

Purpose

Gallbladder cancer is a malignancy with poor prognosis, predominantly resulting from invasion and metastasis. Our previous studies have demonstrated that prostaglandin E₂ (PGE₂), generated by cyclooxygenase 2 (Cox-2), transactivates epidermal growth factor receptor (EGFR), c-Met and β-catenin; thus, enhancing colon cancer cell growth and invasiveness in vitro. To determine whether these findings are applicable to clinical conditions, we examined the expression and cellular localization/co-localization of Cox-2, c-Met, β-catenin, EGFR and c-erbB2 in gallbladder cancer.

Materials and Methods

Thirty-five specimens of invasive gallbladder cancer, 8 in situ carcinoma and 7 adenoma specimens were immunostained with specific antibodies against Cox-2, c-Met, β-catenin, EGFR and c-erbB2. The cellular distribution, localization and colocalization were examined, and the signal intensities quantified in: a) the central area of gallbladder cancer and b) cancer cells forming the invasive front.

Results

Cox-2, c-Met, β-catenin, c-erbB2 and EGFR were over-expressed in 80, 74, 71, 62 and 11% of invasive gallbladder cancers, respectively. β-catenin was expressed in 80% of non-malignant specimens, exclusively in the cell membrane, while the cancer specimens showed cytoplasmic and/or nuclear staining. Significantly higher Cox-2, c-Met and β-catenin expressions were present in cancer cells of the invasive front than in the tumor central areas (p<0.001), and these expressions were significantly (p=0.01) associated with the invasion depth. Co-expressions of Cox-2, c-Met, β-catenin and c-erbB2 were present in 42% of the specimens in cancer cells forming the invasive front.

Conclusion

The overexpressions, and often co-localizations, of Cox-2, c-Met and β-catenin in cancer cells forming the invasive front indicate their local interactions and important roles in invasion.

Citations

Citations to this article as recorded by

EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance
Yeseul Kim, Seungyun Jee, Hyunsung Kim, Seung Sam Paik, Dongho Choi, Su Hyun Yoo, Su-Jin Shin
The Oncologist.2024; 29(8): e1051. CrossRef
Arachidonic acid metabolism as a novel pathogenic factor in gastrointestinal cancers
Weiqin Lu, Aihemaitijiang Aihaiti, Paziliya Abudukeranmu, Yajun Liu, Huihui Gao
Molecular and Cellular Biochemistry.2024;[Epub] CrossRef
Immunohistochemical appraisal of epithelial mesenchymal transition type III in gall bladder cancer
Kamini Yadav, Preeti Agarwal, Madhu Kumar, Sameer Gupta, Medha Mishra, Malti Kumari Maurya, Sumaira Qayoom, Madhu Mati Goel
Indian Journal of Pathology and Microbiology.2023; 66(1): 44. CrossRef
Krukenberg Tumor Related to Gallbladder Cancer in a Young Woman: A Case Report and Review of the Literature
Giulia Grizzi, Michele Ghidini, Margherita Ratti, Marianna D’Ercole, Giulia Tanzi, Annalisa Abbiati, Andrea Celotti, Daniele Spada, Gian Luca Baiocchi, Maria Bonomi
Journal of Personalized Medicine.2023; 13(6): 957. CrossRef
Design, synthesis and evaluation of 4,7-disubstituted 8-methoxyquinazoline derivatives as potential cytotoxic agents targeting β-catenin/TCF4 signaling pathway
Kaushik Neogi, Prashant R. Murumkar, Priyanshu Sharma, Poonam Yadav, Mallika Tewari, Devarajan Karunagaran, Prasanta Kumar Nayak, Mange Ram Yadav
Translational Oncology.2022; 19: 101395. CrossRef
Transcription factor 4 expression and correlation with tumor progression in gallbladder cancer
Kaushik Neogi, Mallika Tewari, Ashish Kumar Singh, Kavyanjali Sharma, Gullanki Naga Venkata Charan Tej, Sumit Singh Verma, Subash Chandra Gupta, Prasanta Kumar Nayak
Journal of Cancer Research and Therapeutics.2022; 18(3): 668. CrossRef
Gallbladder Cancer: Current Multimodality Treatment Concepts and Future Directions
Niklas Sturm, Jasmin Selina Schuhbaur, Felix Hüttner, Lukas Perkhofer, Thomas Jens Ettrich
Cancers.2022; 14(22): 5580. CrossRef
Knockdown of SLC39A4 Expression Inhibits the Proliferation and Motility of Gallbladder Cancer Cells and Tumor Formation in Nude Mice
Min Li, Kun Fan, Bohao Zheng, David Zekria, Tao Suo, Han Liu, Sheng Shen, Houbao Liu, Xiaoling Ni
Cancer Management and Research.2021; Volume 13: 2235. CrossRef
Aspirin and Statin Use and the Risk of Gallbladder Cancer
Kritika Prasai, Sri Harsha Tella, Siddhartha Yadav, Anuhya Kommalapati, Kristin Mara, Mohamed Mady, Mohamed A. Hassan, Nicha Wongjarupong, Natalia Rodriguez-Payan, Mitesh Borad, Tushar Patel, Lewis R. Roberts, Amit Mahipal
Cancers.2021; 13(5): 1186. CrossRef
Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer
Matteo Canale, Manlio Monti, Ilario Giovanni Rapposelli, Paola Ulivi, Francesco Giulio Sullo, Giulia Bartolini, Elisa Tiberi, Giovanni Luca Frassineti
Cancers.2021; 13(22): 5671. CrossRef
UCP2 promotes proliferation and chemoresistance through regulating the NF-κB/β-catenin axis and mitochondrial ROS in gallbladder cancer
Jianhua Yu, Lawrence Shi, Weiguo Lin, Baochun Lu, Yunfeng Zhao
Biochemical Pharmacology.2020; 172: 113745. CrossRef
Prevalence and Clinicopathological Significance of MET Overexpression and Gene Amplification in Patients with Gallbladder Carcinoma
Yeseul Kim, Seong Sik Bang, Seungyun Jee, Sungeon Park, Su-Jin Shin, Kiseok Jang
Cancer Research and Treatment.2020; 52(2): 481. CrossRef
Genetic mutational analysis of β-catenin gene affecting GSK-3β phosphorylation plays a role in gallbladder carcinogenesis: Results from a case control study
Ruhi Dixit, Manoj Pandey, Sunil Kumar Tripathi, Amit Nandan Dhar Dwivedi, Vijay Kumar Shukla
Cancer Treatment and Research Communications.2020; 23: 100173. CrossRef
Overview of current targeted therapy in gallbladder cancer
Xiaoling Song, Yunping Hu, Yongsheng Li, Rong Shao, Fatao Liu, Yingbin Liu
Signal Transduction and Targeted Therapy.2020;[Epub] CrossRef
Targeting Lipid Peroxidation for Cancer Treatment
Sofia M. Clemente, Oscar H. Martínez-Costa, Maria Monsalve, Alejandro K. Samhan-Arias
Molecules.2020; 25(21): 5144. CrossRef
β-Catenin expression is associated with cell invasiveness in pancreatic cancer
Jin Niang Nan, Ok Ran Kim, Myung Ah Lee
The Korean Journal of Internal Medicine.2019; 34(3): 618. CrossRef
Epithelial-to-mesenchymal transition in gallbladder cancer: from clinical evidence to cellular regulatory networks
Sunwang Xu, Ming Zhan, Jian Wang
Cell Death Discovery.2017;[Epub] CrossRef
New Horizons for Precision Medicine in Biliary Tract Cancers
Juan W. Valle, Angela Lamarca, Lipika Goyal, Jorge Barriuso, Andrew X. Zhu
Cancer Discovery.2017; 7(9): 943. CrossRef
Molecular genetics and targeted therapeutics in biliary tract carcinoma
Eric I Marks
World Journal of Gastroenterology.2016; 22(4): 1335. CrossRef
CIZ1 promoted the growth and migration of gallbladder cancer cells
Dexiang Zhang, Yueqi Wang, Yuedi Dai, Jiwen Wang, Tao Suo, Hongtao Pan, Han Liu, Sheng Shen, Houbao Liu
Tumor Biology.2015; 36(4): 2583. CrossRef
Prognostic significance of COX-2 and β-catenin in colorectal carcinoma
Amani Kazem, Khaled El Sayed, Yasser El Kerm
Alexandria Journal of Medicine.2014; 50(3): 211. CrossRef
A genetic model for gallbladder carcinogenesis and its dissemination
S.G. Barreto, A. Dutt, A. Chaudhary
Annals of Oncology.2014; 25(6): 1086. CrossRef
The Role of Epidermal Growth Factor Receptor in Cancer Metastasis and Microenvironment
Takamitsu Sasaki, Kuniyasu Hiroki, Yuichi Yamashita
BioMed Research International.2013; 2013: 1. CrossRef
Significance of epithelial growth factor in the epithelial–mesenchymal transition of human gallbladder cancer cells
Takamitsu Sasaki, Hiroki Kuniyasu, Yi Luo, Daisuke Kato, Satoshi Shinya, Kiyomu Fujii, Hitoshi Ohmori, Yuichi Yamashita
Cancer Science.2012; 103(6): 1165. CrossRef
E-cadherin and c-Met expression in actinic cheilits and lip squamous cell carcinoma
A. Martínez, M.L. Spencer, J. Borlando, M. Flores, I.G. Rojas
Revista Clínica de Periodoncia, Implantología y Rehabilitación Oral.2011; 4(3): 122. CrossRef

10,385 View
63 Download
25 Crossref

Comparison of 30 mg and 40 mg of Mitomycin C Intravesical Instillation in Korean Superficial Bladder Cancer Patients: Prospective, Randomized Study: Chang Wook Jeong, Hwang Gyun Jeon, Cheol Kwak, Hyeon Jeong, Sang Eun Lee; Cancer Res Treat. 2005;37(1):44-47. Published online February 28, 2005; DOI: https://doi.org/10.4143/crt.2005.37.1.44

Abstract PDF PubReader ePub

Purpose

A prospective study was performed to compare the efficacy and safety of intravesical mitomycin C (MMC) instillation for the prophylaxis of bladder cancer at different concentrations (30 mg or 40 mg).

Materials and Methods

Ninety-seven patients that received complete transurethral resection for superficial bladder cancer were divided into two-randomized groups. One group (n=53) received 30 mg and the other group (n=44) received 40 mg dose of MMC weekly for 8 weeks, which was followed monthly for 10 months as maintenance therapy. The recurrence rates and side effects in both groups were recorded. The mean follow-up period was 32.4 months in the 30 mg group, and 32.0 months in the 40 mg group.

Results

The overall one and two year recurrence rates were 19% and 24% in the 30 mg group, and 12% and 22% in the 40 mg group, which was not significantly different (p>0.05). Most of the side effects were mild and transient. Moreover, the rates of the individual side effects were not statistically different in the two groups.

Conclusion

Our comparison of 30 mg and 40 mg intravesical MMC instillation showed no difference in either response or side effects. Thus, we tentatively conclude that we can use 30 mg instead of 40 mg as an intravesical MMC instillation dose.

Citations

Citations to this article as recorded by

Mathematical model of MMC chemotherapy for non-invasive bladder cancer treatment
Marom Yosef, Svetlana Bunimovich-Mendrazitsky
Frontiers in Oncology.2024;[Epub] CrossRef
The Role of Mitomycin C in Intermediate-risk Non–muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis
Pietro Scilipoti, Aleksander Ślusarczyk, Mario de Angelis, Francesco Soria, Benjamin Pradere, Wojciech Krajewski, David D’Andrea, Andrea Mari, Francesco Del Giudice, Renate Pichler, José Daniel Subiela, Luca Afferi, Simone Albisinni, Laura Mertens, Ekater
European Urology Oncology.2024;[Epub] CrossRef
Gestion pratique de l’ECBU au cours des instillations endovésicales de Bacille de Calmette et Guérin (BCG) et de Mitomycine C (MMC)
F. Saint
Progrès en Urologie - FMC.2021; 31(4): F121. CrossRef
Loco-regional deep hyperthermia combined with intravesical Mitomycin instillation reduces the recurrence of non-muscle invasive papillary bladder cancer
Yu-Ching Wen, Liang-Ming Lee, Yung-Wei Lin, Syuan-Hao Syu, Ke-Hsun Lin, Yen-Chun Fan, Hsin-Lun Lee, Benjamin Chung Howe Lai, Hung-Jen Shih
International Journal of Hyperthermia.2021; 38(1): 1627. CrossRef
Adjuvant intravesical therapy based on an in vitro cytotoxicity assay in the management of superficial transitional cell cancer of the urinary bladder
Sunita Saxena, Usha Agrawal, Abhilasha Agarwal, Nandagudi Srinivasa Murthy, Nayan Kumar Mohanty
BJU International.2006; 98(5): 1012. CrossRef

7,868 View
58 Download
5 Crossref

First
Prev
Page of 1
Next
Last

Search